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Abstract
Aims: The aims of this thesis are to characterise clinically, neuropathic cancer pain and
CIBP, to examine the relationship between cancer pain and depression, to explore the
relationship between pain and systemic inflammation and the possibility of pain, depression
and fatigue existing, as a symptom cluster.
Methods: A combination of observational study, systematic review, longitudinal study and
secondary data analysis methodology were utilised, as appropriate to the specific area being
examined.
Results: In neuropathic cancer pain and cancer induced bone pain, worst pain is most closely
associated with the impact of pain on function. In these pain syndromes, breakthrough pain is
often of rapid onset, severe intensity and short duration. The systematic review demonstrated
that there is insufficient evidence to support an interdependent relationship between pain and
depression. The longitudinal study demonstrated that as pain improves, there is a trend
towards an improvement in depression and there is an improvement in the Hospital Anxiety
and Depression Scale (HADS) score. Pain, depression and fatigue cluster together in cancer
patients although there is insufficient information to suggest systemic inflammation as an
underlying cause. There is, however, a significant relationship between pain and systemic
inflammation.
Conclusions: The difficult cancer pain syndromes of neuropathic cancer pain and cancer
induced bone pain are best assessed using "worst pain" as a measure of the impact of pain on
function. Pain and depression in cancer are likely to be related to one another although further
research is needed to confirm this. Pain, depression and fatigue exist together as a symptom
cluster in specific groups of cancer patients. Pain is related to systemic inflammation in
cancer.
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Although the individual cancer patient may have multiple symptoms, several are
particularly common and associated with a significant symptom burden. Pain and
depression are the most common physical and psychological symptoms in cancer
patients (Caraceni and Portenoy, 1999, Lloyd-Williams et al., 2004). Of the various
sub-types of cancer pain, neuropathic cancer pain and cancer induced bone pain
(CIBP) are often difficult to manage and can prove distressing for patients (Caraceni
and Portenoy, 1999). In addition to these physical symptoms, psychological
symptoms, such as depression, are of equal importance. Depression in cancer
patients is associated with significant distress and morbidity (Laird and Mitchell,
2005).
My thesis examines difficult cancer pain, exploring both neuropathic cancer pain and
CIBP. The relationship between cancer pain and depression is examined along with a
potential role of systemic inflammation. The possibility of a specific symptom
cluster combination (pain, depression and fatigue) is explored - Figure 1.
Figure 1 - Thesis overview
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1.2. Difficult Cancer Pain
A single point prevalence survey, published in 1999 on behalf of the International
Association for the Study of Pain (IASP), demonstrated that approximately 90% of
patients with cancer, experience pain (Caraceni and Portenoy, 1999). Cancer pain is
affected by many variables including the tumour site, the extent of local and
metastatic disease, and cancer therapy (Daut et al., 1983).
Despite the high prevalence of pain amongst cancer patients, in a large proportion
pain responds predictably to pharmacological treatment. Studies have shown that
approximately 80% of patients with cancer pain, will respond to treatment using the
World Health Organization Analgesic Ladder for Cancer Pain Relief - Figure 2
(Ventafridda et al., 1987). This high rate of response is usually achieved in specialist
units or when practitioners are familiar and confident with prescribing strong opioid
analgesia. Although this is encouraging, it does mean that there is a remaining 20%
of patients with cancer pain, who will not achieve adequate analgesia with standard
treatment. In non-specialist units, the proportion of patients whose pain is not
controlled using the WHO ladder is expected to be even higher than 20%.
Various factors determine why a proportion of cancer patients do not gain sufficient
pain relief. Factors include the degree of response to opioid analgesics (which can be
Figure 2 - WHO Analgesic Ladder for Cancer Pain Relief
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Introduction
limited by dose related side-effects), breakthrough pain (which can occur despite
sufficient background analgesia) and psychological distress (Colvin et al., 2006). The
underlying pathophysiology of the pain can also play a significant role in successful
analgesia.
Neuropathic cancer pain and CIBP are particularly prevalent pain syndromes
(Caraceni and Portenoy, 1999). It has been reported that the prevalence of
neuropathic cancer pain and CIBP, are 34% and 35% respectively (Grond S, 1996).
Although neuropathic cancer pain and CIBP are common, they are often difficult to
manage (Grond S, 1996). Traditionally a combination of therapies is used to manage
these complex pain syndromes, however commonly used adjuvant analgesics are
often ineffective; while dose related side-effects, constrain the use of opioids. It is
reasonable, therefore, to conclude that neuropathic cancer pain and CIBP present a
significant therapeutic challenge.
1.2.1. Neuropathic Cancer Pain
The IASP defines neuropathic pain as "pain initiated or caused by a primary lesion or
dysfunction in the nervous system" (Merskey and Bogduk, 1994). Neuropathic pain
exists as a diverse group of syndromes, ranging from complex regional pain
syndromes to isolated peripheral nerve lesions.
Neuropathic pain occurs in 34% of cancer patients but it has been suggested that
50% of all difficult to manage cancer pain is neuropathic in origin (Caraceni and
Portenoy, 1999, Grond et al., 1999). Furthermore, uncontrolled neuropathic pain is
associated with anxiety, depression and reduced quality of life (Glover et al., 1995,
Lloyd-Williams et al., 2004).
One of the reasons neuropathic cancer pain is difficult to manage is that, it can be
poorly responsive to opioids. This is because higher doses of opioids are often
required to provide analgesia, compared with other types of pain. The resulting
increase in prevalence of unacceptable side-effects in turn limits dose escalation
(Colvin et al., 2006, Mercadante D, 1999, Fallon and Hanks, 1993).
Introduction
3
Adjuvant analgesics are an important part of our neuropathic pain armamentarium
and include anticonvulsants and antidepressants. Recent evidence-based reviews
have examined the use of adjuvant analgesics for neuropathic pain. Numbers needed
to treat (NNT) are often used to convey a clinically meaningful outcome in pain
studies, and although NNTs can be misleading, in this setting their appropriateness
has been validated (Moore and McQuay, 1999). Anticonvulsants, such as gabapentin
and pregabalin, are commonly used as adjuvant analgesics in neuropathic pain. To
date, they have been shown to have a higher NNT than older anticonvulsants
(Finnerup et al., 2005).
The use of antidepressants in neuropathic pain has also been examined (Saarto and
Wiffen, 2007). In this study, tricyclic antidepressants (such as amitriptyline) were
shown to provide at least moderate pain relief (NNT= 3.6). Data have also supported
the use of newer antidepressants such as Venlafaxine (NNT= 3.1) (Saarto and
Wiffen, 2007).
In summary, the widely-used adjuvant analgesics in neuropathic pain (amitriptyline
and gabapentin) have a NNT of approximately 3 and 5 respectively (Finnerup et al.,
2005). Newer adjuvant analgesics have even higher NNTs. This means that, at best,
only one in every three patients will get any analgesic benefit from these drugs.
Furthermore, adjuvant analgesics, either alone or in combination with opioids, may
result in unacceptable side-effects which might hinder their use. Although treatments
for neuropathic pain have been studied extensively, the clinical characteristics of
neuropathic cancer pain have never been examined in a robust, systematic fashion.
Clinical characterization is fundamental to gain a common baseline understanding of
neuropathic pain, the future development of novel neuropathic pain treatments and to
guide future research.
1.2.2. Cancer Induced Bone Pain
CIBP is the most common cause of cancer pain (Mercadante, 1997, Banning et al.,
1991, Coleman, 1997). It is a major cause of morbidity in patients with cancer and
commonly results in either hospice or hospital admission (Coleman, 1997, Neville-
Webbe and Coleman, 2003). CIBP adversely affects performance status and
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increases psychological symptoms such as anxiety and depression (Portenoy and
Hagen, 1990, Bruera et al., 1995, Portenoy et al., 1999).
CIBP can be a consequence of metastatic disease or due to a primary tumour of the
bone. Bone is the most common site of metastatic disease (Coleman, 1997). An
accurate prevalence is not known as this is very much dependent on the primary
tumour site and the likelihood that it metastasizes to bone. Data from post mortem
studies have shown that bone metastases are present in 85% of patients who have
died from lung, breast or prostate cancer (Nielsen et al., 1991).
Radiotherapy is currently regarded as the gold-standard treatment for CIBP. The
mechanisms of analgesia from radiotherapy for CIBP are not fully understood,
however it is becoming clear that tumour cell death is not the only mechanism (van
As et al., 2007). The primary tumour site does not seem to affect responsiveness to
radiotherapy and there is no difference in analgesic benefit from single or multiple
fractions of radiation (Price et al., 1986, Hoskin et al., 1992).
Despite being a widely-used treatment, radiotherapy may not always confer an
analgesic benefit. A systematic review examined the role of radiotherapy in the
treatment of CIBP (McQuay et al., 2000). This showed that radiotherapy provided
complete analgesic benefit in only one in four patients.
Bisphosphonates are also used in the treatment of CIBP. These act in a variety of
ways including the inhibition of osteoclast activity (van Beek et al., 2003).
Bisphosphonates also cause apoptosis of osteoclasts and inhibit the growth of tumour
cells through various mechanisms. It has been shown that bisphosphonates may have
some effect in the acute management of CIBP but are less effective than strong
opioids or radiotherapy (Wong and Wiffen, 2002). In patients treated with
bisphosphonates for pain relief, an NNT of 11 was reported at four weeks meaning
that only one in eleven patients treated, will gain some analgesic benefit. There is
thus insufficient evidence to recommend bisphosphonates alone as an adequate
solution to the problem of CIBP.
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Although treatments for CIBP have been studied extensively, current therapies are
likely to be ineffective for a large proportion of patients. Despite the time invested in
developing treatments for CIBP, it has never been characterized in the clinical
setting. It is essential to understand completely the characteristics of CIBP in order to
inform the development of new treatments and direct research.
1.2.3. Breakthrough Cancer Pain
Cancer pain, and in particular neuropathic cancer pain and CIBP, rarely exists as
single entities but are often a combination of different types of pain. This pain can be
separated into:
Background Pain
Breakthrough Pain - which can be divided into:
• spontaneous pain at rest
• incident pain (related to either movement or other
action such as coughing or straining at stool)
Breakthrough pain has been defined as "a transitory exacerbation of pain experienced
by the patient who has relatively stable and adequately controlled baseline pain"
(Portenoy et al., 2004). Varying terminology has been used to describe breakthrough
pain. Incident pain is accepted as any pain precipitated by an event (Cleary, 2005).
Episodic pain has been defined as "any pain that varies with time" (Swanwick et al.,
2001). Advocates of the term "episodic pain" have argued that using this definition,
includes patients who have no background pain but still suffer from episodes of
breakthrough pain. In recent years however a consensus has been reached that
breakthrough pain can only be present in combination with adequately controlled
background pain.
The management of breakthrough pain presents a significant therapeutic challenge as
some analgesics can be ineffective. Although there is some evidence for the use of
short acting opioids for breakthrough pain (Zeppetella and Ribeiro, 2006), titration of
opioids to doses required to deliver sufficient analgesia in spontaneous neuropathic
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and bone pain usually results in unacceptable opioid side-effects, especially sedation.
Thus, the use of opioids in the management of breakthrough pain is limited. This
thesis explores breakthrough pain in neuropathic cancer pain and CIBP.
1.3. Psychological Components of Cancer Pain
Although pain is one of the most common symptoms in cancer, psychological
symptoms should be assessed and viewed as a continuum with physical symptoms.
In cancer patients, psychological wellbeing is equally as important as the treatment
of physical symptoms. Physical and psychological problems can clearly coexist
without being strongly related; however my thesis is that they are often related.
1.3.1. Cancer Pain and Depression
Pain has been defined as "an unpleasant sensory and emotional experience associated
with actual or potential tissue damage, or described in terms of such damage"
(Merskey and Bogduk, 1994). This definition illustrates clearly that pain is not a
singular phenomenon but a complex process involving both physical and
psychological components. It is now clear that the midbrain plays a major role in the
processing and integration of factors such as anxiety, depression, sleep deprivation
and fear into the pain pathways. In addition, this is also the area of a descending and
ascending loop which can inhibit or accentuate the pain processing - Figure 3.
Introduction
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Figure 3 - Interaction between pain and psychological symptoms
Fear, anxiety, sleep, punishment





The brain can talk back to the spinal cord
PAG = periaqueductal gray
RVM = rostroventromedial medulla





Slide reproduced by kind permission of Professor AH Dickenson, University College London.
As pain and depression are common symptoms in cancer patients, the possibility of a
relationship between these symptoms has been raised. These symptoms could be
related in several ways.
1) Symptoms co-exist
Pain and depression are both common symptoms. It may be the case that as
they are common they often exist together, but independently.
2) Symptoms co-exist and are related
One symptom may impact directly on the other. Patients who have pain may
have increased levels of emotional distress which, if severe enough, this
could result in depression. Similarly emotional distress and depression may
amplify pain. As pain is a complex phenomenon that can result in physical
and psychological symptoms; it would thus seem reasonable to accept that an
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increase in depression per se, may magnify the emotional component of pain,
increasing the severity of the overall pain experience.
3) Symptoms co-exist and share common pathophysiology.
It has been demonstrated that pain and depression both affect the same area
of the cerebral cortex (Giesecke et al., 2005, Smith et al., 2002). Furthermore,
several of the neurotransmitters involved in pain pathways have also been
implicated in the pathophysiology of depression (Fava, 2003). Abnormalities
of the neurotransmitter systems involving norepinephrine (NE) and serotonin
(5-HT) have been shown to be abnormal in depression. These
neurotransmitters are also involved in descending pain pathways and may
modulate pain. As pain and depression share these common entities
(anatomically and chemically), it is reasonable to consider that pain and
depression may share a common pathophysiology.
As pain and depression are often present together clinically, it is possible that they
may be linked at the molecular level. It would seem unlikely that a single pathway or
interaction exists in isolation; it is more likely that the physical impact of one
symptom on another, in addition to a common underlying pathophysiological
pathway is implicated. This thesis examines the evidence, thus far, for a possible link
between pain and depression.
In the non-malignant setting, pain and depression have been studied (Bair et al.,
2004). The presence of pain was shown to be a strong predictor of depression and
increased levels of pain were associated with a decreased response to depression
treatment (Bair et al., 2004). Although this would suggest an association between
pain and depression, this association has not been studied extensively in a cancer
population.
A systematic review of cancer pain and depression would allow an appraisal of the
current evidence of the relationship between these two symptoms. It has been shown
in cancer, that an improvement in pain results in an improvement in quality of life
(Thienthong et al., 2006). However, the specific relationship between pain and
depression in cancer has not been studied. A longitudinal study, where pain is treated
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while depression is observed, would allow a dynamic assessment of the relationship
between these symptoms. The longitudinal study presented herein examines the
relationship between pain and depression when one of these symptoms is altered
whilst no intervention is given to the other. This allows a direct examination of the
impact of one symptom on another.
1.4. Pain and Systemic Inflammation
Pain is the commonest symptom in cancer patients whilst cancer, per se, is associated
with systemic inflammation (Mantovani et al., 2008). Pain and inflammation have
been associated for centuries. In the earliest definitions of inflammation, one of the
key constituents was dolor (or pain). This observation that inflammation is associated
with pain has been substantiated with clinical experience and more recently, a basic
science evidence base.
Systemic inflammation, mediated by a pro-inflammatory cytokine drive, has been
associated with pain in animal and human models (Watkins and Maier, 2000). As
there is a high prevalence of pain and inflammation in cancer, the relationship
between these is of interest. The study presented herein examines the relationship
between pain and inflammation in a cohort of cancer patients.
1.5. Symptom Cluster: Pain, Depression and Fatigue
Cancer symptoms rarely exist in isolation, with some studies reporting a median of
11 symptoms (Walsh et al., 2000). Whilst multiple symptoms are often present, the
relationship between these symptoms may affect both their underlying biological
basis and optimal treatment.
In the last seven years the concept of symptom clustering in cancer patients has been
discussed in the literature. A symptom cluster has been defined as " three or more
concurrent symptoms that are related to each other" (Dodd et al., 2001a). Symptoms
simply co-existing together is insufficient for them to be labelled as a cluster (Dodd
et al., 2004). To be classified as a cluster, symptoms need to be related to one another
and occur concurrently. Pain, depression and fatigue are highly prevalent in cancer
patients and often exist together (Bower et al., 2000, Gaston-Johansson et al., 1999).
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The possibility of these existing together as a symptom cluster has been raised,
although there is currently insufficient evidence to support this (NIH, 2002).
Evidence of pain, depression and fatigue existing together as a symptom cluster,
would have a significant impact on the approach to the treatment of these symptoms.
It is clear that establishing the existence of this cluster of common cancer symptoms
is fundamental. Common underlying pathways between symptoms would seem a
possibility when symptoms often exist in unison. Systemic inflammation, which is
known to exist in cancer, may be one possible underlying mechanism. The potential
existence of a symptom cluster of pain, depression and fatigue is explored herein and
a possible common underlying mechanism for this is examined.
1.6. Aims of this Thesis
This chapter emphasizes that difficult cancer pain, both alone and in combination
with depression, is a common symptom in the cancer patient. It is clear that pain is
complex but that cancer adds another layer to this complexity.
Common therapies for neuropathic cancer pain and CIBP are often sub-optimal.
Clinical characterization of these pain syndromes is fundamental to developing
appropriate treatments for these conditions. Although pain and depression are both
common in cancer patients, little is known about the relationship between these
symptoms. The potential role of systemic inflammation and its effect on pain is of
interest in the cancer setting. The existence of pain, depression and fatigue existing
together as a symptom cluster has also been questioned in the literature although this
has not been identified formally in any robust studies.
The aims of this thesis are to characterise clinically, neuropathic cancer pain and
CIBP, to examine the relationship between cancer pain and depression, to explore the
relationship between pain and systemic inflammation and the possibility of pain,
depression and fatigue existing, as a symptom cluster.
Introduction
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1.6.1. Summary of Aims
Aim 1: To characterize clinically, neuropathic cancer pain.
Aim 2: To characterize clinically, CIBP.
Aim 3: To undertake a systematic review of the literature examining the relationship
between cancer pain and depression.
Aim 4: To assess the effect of pain on depression and the longitudinal relationship of
these two entities.
Aim 5: To examine the relationship between pain and inflammation.




Chapter 2. A Characterization of the Temporal
Components of Neuropathic Cancer Pain
2.1. Introduction
Neuropathic pain is one of the most common symptoms in patients with cancer, with
a prevalence of 34% (Caraceni and Portenoy, 1999). Approximately 50% of all
difficult to manage cancer pain is neuropathic in origin (Grond et al., 1999).
Uncontrolled neuropathic pain is associated with anxiety and depression and can
affect quality of life adversely (Glover et al., 1995, Lloyd-Williams et al., 2004).
As discussed in 1.2.1, neuropathic pain can be challenging to manage with standard
treatments. Opioid analgesics can be used to treat non-malignant neuropathic pain
and their efficacy has been demonstrated with a NNT of approximately 2.5 (Finnerup
et al., 2005). In neuropathic cancer pain however the doses needed to provide
analgesia often result in unacceptable side-effects (Colvin et al., 2006, Mercadante et
al., 1999, Fallon and Hanks, 1993). Adjuvant analgesics are also key in our
neuropathic pain armamentarium; although the choice of adjuvant analgesic is not
based on potency superiority nor on underlying pathophysiology. In addition, at best
they have a NNT of 3 (Finnerup et al., 2005).
Traditionally, a combination of opioid and adjuvant analgesics is used to manage
neuropathic pain, however this may not provide adequate analgesia. To achieve
effective pain control, a detailed understanding of the individual components of
neuropathic pain and its clinical features is needed.
Neuropathic pain can be categorized by the underlying pathophysiology and while
this may be useful in some settings, in day-to-day clinical practice, knowledge of the
underlying pathophysiological process has little impact on the choice of treatment.
Neuropathic pain, in keeping with other pain syndromes, exists as a combination of
background pain and breakthrough pain. Breakthrough pain can be either
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spontaneous or incident-related (e.g. movement, coughing etc). Each of these
components needs to be assessed. Although there has been a considerable amount of
research into neuropathic cancer pain, the practical clinical features of the different
components have never been characterized formally in a clinical setting.
This would be useful for several reasons:
1. To act as a template to aide more accurate clinical assessment
2. To provide greater understanding of why neuropathic cancer pain may be
difficult to control
3. To improve assessment in research studies
4. To help with management decisions
The aim of this study was to characterize the clinical features of neuropathic cancer
pain.
2.2. Patients and Methods
2.2.1. Overview
The study design used was a cross sectional prospective survey of patients with
neuropathic pain related to the underlying malignancy. Ethical approval was
obtained. Written informed consent was provided by all patients. Procedures of the
Declaration of Helsinki and Good Clinical Practice were followed. The study was
conducted in a regional oncology centre in the UK, where specialist oncology
services are provided to a population of approximately 1.5 million.
2.2.2. Patients
Participants were inpatients or outpatients, attending the study centre. All were over
18 years of age and had a histologically proven cancer diagnosis. Eligible patients
had a neuropathic pain syndrome which was defined as per recognised criteria and
related to the underlying malignancy (Portenoy, 1989, Caraceni and Portenoy, 1999).
To be eligible for inclusion, the neuropathic pain (referred to as the index site pain)
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had to have been symptomatic in the previous 24 hours. Patients felt to be in the last
week of their lives or who were unlikely to be able to complete the study due to their
clinical condition, were excluded. Patients who did not have neuropathic cancer pain
or in whom the origin of their pain was unclear were excluded.
2.2.3. Methods
A single interview was conducted with each patient. Demographics and information
concerning each patient's underlying malignancy were gathered. Details of all
analgesic drugs taken in the preceding 24 hours were recorded. For ease of
comparison, opioid doses were converted to oral morphine equivalents (Morphine
equivalent daily dose - MEDD) using a recognised and accepted conversion table
(Fallon et al., 2009). Analgesics were classified as simple, weak opioids or strong
opioids and corresponded with steps 1, 2 and 3 respectively, on the World Health
Organization Ladder for Cancer Pain Relief - Figure 2 (Azevedo Sao Leao Ferreira et
al., 2006).
Pain in the index pain site in the preceding 24 hours, was assessed using pain
questionnaires. All patients completed the Brief Pain Inventory (BPI) and from this
group, those who had breakthrough pain completed a breakthrough pain
questionnaire (BTPQ) - Appendix 1.
Breakthrough pain was defined as pain that increased from a lower to a greater pain
intensity by greater than two points (on a 0-10 Visual Analogue Scale (VAS)). This
ensured that only those patients with definite breakthrough pain, were classified as
such.
2.2.4. Pain Assessment
2.2.4.1. Brief Pain Inventory
The BPI is a multidimensional pain assessment tool that has been validated
extensively in multinational studies of cancer pain epidemiology and clinical trials of
analgesics (Cleeland and Ryan, 1994, Portenoy et al., 1999). It has two sections. One
section assesses pain intensity and percentage relief from medication whilst the
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other section assesses the effect of pain on various aspects of function (Daut et al.,
1983).
Intensity - The pain intensity section assesses worst pain, average pain, least pain and
pain right now. This is done on a 0 -10 scale with 0 indicating no pain and 10
indicating worst pain imaginable. The "relief from medication" question assesses
percentage relief provided by current analgesia and this is rated on a 0-100 scale, 0
indicating no relief and 100 indicating complete relief.
Interference - The effect of pain on general activity, mood, walking, work,
relationships, sleep and enjoyment of life are assessed. This is done on a 0-10 scale
with 0 indicating pain does not interfere and 10 indicating pain completely interferes
with the specific component. The total BPI interference score (sum of individual
interference question scores) gives a useful indicator of the effect of pain on various
aspects of physical, psychological and social function (Portenoy et ah, 1992).
The BPI can be assessed using individual questions in isolation (e.g. worst pain), the
sum of either the intensity or interference subscales, or the cumulative total of the
intensity and interference subscales.
2.2.4.2. Breakthrough Pain Questionnaire
At the time of the study, a validated BTPQ had not been developed and the
questionnaire used was based on previously published work (Portenoy et ah, 1999).
The BTPQ allowed patients' breakthrough pain to be described in greater detail and
included assessment of severity of background and peak pain intensity. Further
questions determined the frequency, speed of onset, duration and breakthrough pain
predictability, all factors likely to be important clinically.
2.2.5. Data Analysis and Statistics
Demographics and pain characteristics were analysed. This analysis was
subsequently summarised using proportions, means and standard deviations (SD) or
medians and inter-quartile ranges (IQR).
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Aspects of the BPI were analysed in further detail and BPI "average pain" and
"worst pain" scores were then compared to the total BPI interference score.
Regression analyses between these variables were then run. Subsequently,
relationships between these pain scores and pain related interference with function
scores were determined.
A subgroup analysis of the BPI was undertaken to compare those who had
breakthrough pain with those who did not, using Mann-Whitney tests.
2.3. Results
The patient demographics are shown in Table 1. Thirty patients were recruited.
Eighteen (60%) were male and the mean age was 61.5 years (SD 11.29, range 39-
81). A wide variety of tumour sites were represented, however breast and lung cancer
were the most common. Patients were either performance status 1, 2 or 3 (ECOG)
with twenty-one patients (71%) performance status 2, which was the commonest
group. Sixteen patients (53%) were inpatients and the remainder were outpatients.
Analgesia and tumoricidal therapy is shown in Table 2. Twenty-two patients (73%)
were taking strong opioids. These included morphine, diamorphine, oxycontin,
hydromorphone and fentanyl. The mean MEDD was 130.5mg (range 0 - 620mg).
Twenty patients (67%) were taking gabapentin, amitriptyline or a combination of
both of these. Three patients were using lidocaine patches.
Sixteen patients (53%) were not receiving any tumoricidal treatment while the
remainder were receiving either chemotherapy, radiotherapy, hormonal treatment or
a combination of these.
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Unknown Primary 2 3
Extent of disease
Local disease 1 3
Bone metastases 6 20
Multiple metastases 10 33
Unknown 13 43
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Weak Opioid (e.g. Codeine) 1 3





Gabapentin & amitriptyline 2 7









*Simple - e.g. acetaminophen/paracetamol
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2.3.1. Pain Characteristics
Results of the BPI are shown in Figure 4. The median "average pain" was 4 and the
median "worst pain" score was 7. The multiple regression analysis showed that the
BPI worst pain score correlated more strongly with the BPI total interference score,
than the BPI average pain score. The coefficient for worst pain was 5.54 (SE 2.14,
p=0.016) and for average pain it was -2.40 (SE 2.29, p=0.30). Therefore worst pain
relates more strongly to the effect of pain on function.
The BPI scores of those patients without breakthrough pain and those with
breakthrough pain were compared. The median (IQR) BPI average pain for those
without and those with breakthrough pain was 6 (4-7.5) and 4 (3-5) respectively. The
difference in average pain between these groups was statistically significant
(p<0.05). The median (IQR) BPI worst pain for those without and those with
breakthrough pain, was 8 (6.5-9) and 7 (5.5-8) respectively. There was no
statistically significant difference between the scores in these two groups (p<0.05
level).
Patients who had breakthrough pain had lower total BPI interference scores than
those who did not have breakthrough pain (median [IQR]; 30 [14.5-45] vs 43 [23-
49.5] respectively). However, this did not reach levels of statistical significance
(p<0.05 level).
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Figure 4 - Brief Pain Inventory - Neuropathic cancer pain
Box and whisker plot representing the median value, with 50% of the data falling within the box
[Interquartile range]. The whiskers extend to the 5'h and 95'h percentiles. *=outlier
2.3.2. Breakthrough Pain
Results of the BTPQ are shown in Table 3. Nineteen patients (63%) met the study
criteria for breakthrough pain. The median number of episodes of breakthrough pain
(per 24 hours) was 3 and the median severity of the breakthrough pain episodes was
7 (based on a 0-10 VAS). Breakthrough pain was unpredictable in 11 patients (58%)
which included those patients who had onset of pain in less than 10 seconds.
Seventeen patients (90%) had a speed of onset of breakthrough pain (time from being
first aware of pain, to pain reaching its peak) of less than 5 minutes. Ten patients
(53%) had breakthrough pain of less than 30 minutes duration. Breakthrough pain
was rapid onset (less than 5 minutes) and short duration (less than 15 minutes) in 8
patients (42%).
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Table 3 - Breakthrough Pain Questionnaire - Neuropathic cancer pain
Median IQR
Number of BTP episodes in 24 hours
3 1 -4.5
Severity of BTP episodes
7 5.5 - 8














Median (IQR) 16-30 mins ( 1-15 — 31-60 mins)
Rapid Onset (<5 Mins) & Short Duration (<15mins)
8 42
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2.4. Discussion
The study represents the first clinical characterization of the practical clinical aspects
of neuropathic cancer pain. Previous work examining various aspects of neuropathic
pain has been undertaken, however by focussing solely on the clinical characteristics,
valuable information on neuropathic cancer pain, has evolved.
2.4.1. Worst Pain
The results suggest that worst pain is often higher than average pain, in neuropathic
cancer pain. Worst pain was three points higher than average pain (on a 0-10 VAS)
which is clinically significant (Farrar et al., 2000). Neuropathic pain has been
associated with a higher pain intensity in larger studies and these results are in
keeping with this (Portenoy et al., 1999). Worst pain also correlated more strongly
with the interference score of the BPI than average pain. This suggests that worst
pain is a more useful measure of the effect of pain on interference on function than
average pain. Furthermore, worst pain is predictive of interference on function over
and above average pain, but not vice versa.
2.4.2. Breakthrough Pain
The findings suggest that breakthrough pain is frequently present in neuropathic
cancer pain with 63% of our study population having breakthrough pain. Median
worst pain was higher than the average pain. Breakthrough pain was often of sudden
onset (less than 5 minutes) and unpredictable. In approximately 40% of those
patients with breakthrough pain, it was of rapid onset and short duration.
Breakthrough pain can have a considerable impact on, and has been shown to be
related to, overall poor pain control (Mercadante et al., 1992, Mercadante et al.,
2002a). Breakthrough pain is also associated with greater functional impairment
(Portenoy et al., 1999), increased anxiety and depression (Portenoy et al., 1999) and
may adversely affect healthcare costs (Fortner et al., 2002). The importance of
breakthrough pain in other pain states (such as CIBP) has been highlighted. The
findings suggest that breakthrough pain is also an important feature of neuropathic
cancer pain.
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2.4.3. Comparison - No breakthrough pain group versus breakthrough
pain group
Patients without breakthrough pain had statistically significant higher average pain
scores than those with breakthrough pain. Worst pain scores were also higher in the
group with no breakthrough pain but this did not reach levels of statistical
significance (at the p>0.05 level). Patients without breakthrough pain had higher BPI
interference scores than those with breakthrough pain but this did not reach levels of
statistical significance.
It could be postulated that one reason for this is that in neuropathic cancer pain,
patients without breakthrough pain have higher background pain levels than those
with breakthrough pain. This transfers into pain flares being smaller in magnitude.
As those without breakthrough pain had higher levels of average pain, it is assumed
that their background pain was generally less well controlled resulting in the higher
BPI interference scores.
2.4.4. Relationships to previous studies
Studies examining cancer pain in general have been undertaken, however these have
encompassed all types of cancer pain. It is thus difficult to compare these findings to
other published work. Pain descriptors in neuropathic cancer pain have been
examined previously although a detailed clinical characterization has never been
performed (Mystakidou et al., 2007a). Breakthrough cancer pain in general has been
described in the literature but breakthrough neuropathic cancer pain has not been
described in isolation (Portenoy et al., 1999, Caraceni et al., 2004). By examining
neuropathic cancer pain in detail, specific features of breakthrough pain in this group
have been identified.
Breakthrough pain in general has been demonstrated to be associated with greater
functional interference, however in subgroups with generally very poorly controlled
background pain this could be different (Portenoy et al., 1999). These findings in
neuropathic pain support the latter.
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Studies of the temporal characteristics of breakthrough cancer pain (in all types of
pain) have previously been conducted. Median durations of breakthrough pain range
from 15 minutes,(Hwang et al., 2003) to 30 minutes (Hwang et al., 2003, Portenoy
and Hagen, 1990, Gomez-Batiste et al., 2002). Breakthrough pain has also been
reported as being unpredictable in 27% (Portenoy and Hagen, 1990) to 58% (Hwang
et al., 2003) of patients. In these studies all types of cancer pain were included and
this may explain these variable characteristics.
2.4.5. Implications for Practice
The findings presented highlight some issues regarding the treatment of neuropathic
pain. The temporal characteristics of neuropathic breakthrough pain can make it
challenging to manage. As breakthrough pain is often unpredictable, of rapid onset
and short duration, standard immediate release (IR) opioids are likely to be effective
only in some cases. Newer rapid onset, short duration opioids are now available and
these may be of a benefit to some patients. Nevertheless, there may be a cohort of
patients with neuropathic breakthrough pain for whom these will not be effective.
Opioids have been shown to be of use in neuropathic pain and their use is advocated
as a first line therapy in neuropathic cancer pain (Dworkin et al., 2007). Tricyclic
antidepressants (e.g. amitriptyline) and anticonvulsants (e.g. gabapentin) have also
been recommended for neuropathic pain, although they have a NNT of
approximately 3 and 5 respectively (Finnerup et al., 2005). Most of the patients in the
study were taking strong opioids in addition to standard adjuvant analgesics for
neuropathic pain, yet despite this analgesia was sub-optimal. Previous work has
suggested that, at best, only 60% of patients will get some relief from their
neuropathic pain. The findings presented would suggest that a considerable
proportion of patients with neuropathic pain, will only achieve a degree of analgesia
with standard therapies.
Basic science work has demonstrated that a range of pathophysiological processes
exist in neuropathic pain (Urch and Dickenson, 2008). It is thus logical to target the
various mechanisms which are present in neuropathic pain. The successful treatment
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of neuropathic pain may require the use of several different therapies each targeting a
different underlying process.
2.4.6. Limitations
The main criticism of this study is the small sample size, although some statistical
inference can be drawn from the results. The study population were all under the care
of oncologists and attending a regional oncology centre. Although this included
inpatients, outpatients, and all tumour types, the sample may not be truly
representative of a general cancer population with neuropathic pain. Patients in the
study were not known to a specialist palliative care or pain service. Therefore
patients who may have had more severe pain may have been missed. Patients who
were near the end of life were also excluded and such a population may have a
greater degree of pain.
The criteria for identifying breakthrough pain could be debated. Previous studies
have excluded patients who did not have regular episodes of breakthrough pain or
who were not on regular strong opioids (Portenoy and Hagen, 1990, Portenoy et al.,
1999, Hwang et al., 2003). The rationale for this was to exclude patients who had
transitory flares of pain that were likely to settle spontaneously. By excluding such
patients in this study, a true picture of the diversity of breakthrough pain, would not
be achieved.
Analgesics taken by patients in the study may, in theory, have altered the features of
breakthrough pain. No patients in the study were taking rapid-onset, short acting
opioid preparations (e.g. oral transmucosal fentanyl citrate) however some were
taking standard IR opioids. At best IR opioids have an onset of effect at 30 minutes
and a peak effect at 60 minutes (Bailey and Farley, 2006). As the study population
had breakthrough pain which was usually of less than 30 minutes duration, it is
unlikely that IR opioids would have affected this. It would have been interesting to
note the opioid side-effect profile, particularly in those patients with poor
background pain control. This aspect would be important in a future larger study. In
addition future work in this area would need to address the other variables such as
background opioid analgesia, breakthrough analgesia and the effects of this on
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breakthrough pain. Accommodating such variable is challenging and highlights the
tension between the internal and external validity in future study design.
2.5. Conclusion
Neuropathic cancer pain continues to be a clinical challenge. Worst pain is a useful
indicator in the assessment of neuropathic pain and the impact of this on patient
function. Breakthrough pain is often unpredictable and short duration and this has
implications for practice. Despite the use of strong opioids and adjuvant analgesics,
neuropathic cancer pain remains difficult to manage.
To treat neuropathic cancer pain adequately a greater understanding of the
underlying pathological processes and also the clinical characteristics is required.
This small characterization study highlights some key clinical features of neuropathic
cancer pain; however larger characterization studies in the broader cancer population
are needed.
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Chapter 3. A Characterization of Cancer Induced
Bone Pain
3.1. Introduction
Cancer-induced bone pain is the most common cause of cancer pain (Banning et al.,
1991, Coleman, 1997, Mercadante, 1997). Common malignancies such as breast and
prostate cancer frequently metastasize to bone. Increased morbidity, reduced
performance status, increased anxiety and depression, and a reduced quality of life
are associated with CIBP (Portenoy and Hagen, 1990, Portenoy et al., 1999, Bruera
et al., 1995). Uncontrolled CIBP is a common cause of hospital or hospice
admission, with up to 85% of patients with bone metastases having pain (Coleman,
1997, Mercadante, 1997, Neville-Webbe and Coleman, 2003).
CIBP is not a single entity but instead exists as background (tonic) pain, spontaneous
pain at rest and movement-related (incident) pain (Portenoy et al., 1999). These
components can be present either solely or in combination and the approach to the
management of each element needs to be addressed differently.
As discussed in 1.2.2, current common treatments for CIBP can be suboptimal
making this a considerable therapeutic challenge. Palliative radiotherapy remains the
most effective anticancer treatment for CIBP, but it does not always provide total
analgesia. Only 41% of patients achieve 50% pain relief within 4 weeks of treatment
whilst only one quarter of patients will gain complete pain relief (McQuay et al.,
2000, Chow et al., 2007). Bisphosphonates are proven to delay symptomatic skeletal
events in certain tumour types, however their efficacy in the acute management of
CIBP remains unproven (Ross et al., 2003).
Opioid analgesia is the main pharmacological treatment for CIBP, although this has
several limitations. Titration of opioids to doses that control spontaneous pain at rest
and movement-related bone pain, usually results in unacceptable opioid side-effects
(Mercadante and Arcuri, 1998, Portenoy et al., 1999). In recent years the
pharmaceutical industry has been developing short acting oral opioids to provide
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rapid onset, short duration analgesia for use in breakthrough pain in CIBP and other
pain types. Their efficacy in routine clinical practice is as yet unproven.
Although considerable time has been spent in developing new analgesics for CIBP, it
has never been characterized in the clinical setting. Laboratory models of CIBP
indicate that the mechanisms underlying CIBP have similarities and differences to
other pain states such as inflammatory and neuropathic pain. Central sensitization is
common to CIBP and neuropathic cancer pain and may explain the beneficial effects
of gabapentin in both neuropathic pain and CIBP states (Donovan-Rodriguez et al.,
2005). In studies comparing CIBP to inflammatory pain, vast variation in opioid
doses required to achieve analgesia, have been reported, suggesting different
mechanisms (Luger et al., 2002). These similarities and differences may have
implications for clinical practice. A detailed clinical characterization of CIBP should
underpin improved patient management. It may also allow symptoms and signs to be
linked with underlying mechanisms and inform further research in this area.
The aim of this study was to characterize CIBP in a cross-section of patients with
radiologically proven bone metastases and pain.
3.2. Patients and Methods
3.2.1. Overview
The study was part of the same study group as described in 2.2.1. and was a cross
sectional prospective survey of patients with CIBP attending the study centre. All
necessary ethical and regulatory procedures were as described in 2.2.1.
3.2.2. Patients
Patients were eligible if they had a radiologically proven site of bone metastasis and
had corresponding pain (referred to as the index pain site) which had been
symptomatic in the preceding 24 hours. If more than one type of pain was present,
the index pain site had to be that chosen by the patient to be their most problematic
pain. All patients were 18 years of age or over and were either inpatients or
outpatients.
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Patients who were unlikely to be able to complete the study protocol due to their
clinical condition or who were in the last week of life, were excluded. In addition,
patients who had pain produced by mechanisms other than CIBP or in whom the
origin of their pain was unclear, were excluded.
3.2.3. Methods
Once consent had been obtained, a single interview was conducted with each patient.
Demographics and information concerning the patient's underlying malignancy, was
gathered. Types and doses of analgesic drugs (including non-steroidal anti¬
inflammatory drugs [NSAIDs]) taken in the preceding 24 hours were recorded. As
per 2.2.3 opioid doses were converted to oral morphine equivalents (Morphine
equivalent daily dose - MEDD) using a recognised conversion table, to allow
comparison (Fallon et al., 2009). Analgesics were classified as either simple, weak
opioids or strong opioids and correlated with steps 1, 2 and 3 respectively on the
World Health Organisation Ladder for Cancer Pain Relief - Figure 2 (Azevedo Sao
Leao Ferreira et al., 2006).
3.2.4. Pain Assessment
Pain in the index site in the preceding 24 hours, was assessed using several pain
questionnaires to assess the different components of CIBP. All patients completed
the Brief Pain Inventory (BPI) and a screening question to identify breakthrough
pain. The sub-group of patients who had breakthrough pain also completed a
Breakthrough Pain Questionnaire (BTPQ). Breakthrough pain was defined as pain
that increased by 2 points or more (on a 0-10 Visual analogue scale [VAS]) from
their background pain.
The BPI and BTPQ have been discussed previously in section 2.2.4.
3.2.5. Statistics and Analysis
Patient demographics and pain characteristics were summarized using proportions,
and means and standard deviations (SDs) or medians and inter-quartile ranges
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(IQRs). BPI "average pain" and "worst pain" scores were related to the BPI
interference scale using multiple linear regression. A further analysis of the BPI
interference scale was undertaken to compare those patients with, and those without,
breakthrough pain, using Mann-Whitney tests.
3.3. Results
The basic demographics of all patients are shown in Table 4. Fifty-five patients
were recruited of which 27 (49%) were male. The mean age was 63.5 years (SD
11.6, range 37-87). Breast and prostate cancer were the most common primary
tumour groups. Twenty-eight (51%) patients were performance status 2 whilst 32
patients (58%) were outpatients, with the remainder receiving inpatient oncology
centre care.
Patient's current analgesia and tumoricidal therapy is shown in Table 5. Seventeen
patients (31%) were taking simple analgesia such as acetaminophen whilst 10
patients (18%) were using weak opioids. Twenty-one patients (38%) were taking a
strong opioid which included morphine, diamorphine, oxycontin, hydromorphone,
and fentanyl. The mean MEDD was 66.9mg (range 0-350mg).
While the majority of patients were receiving some form of tumoricidal therapy, 34%
were not on any active treatment at the time of the study.
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Extent of disease
Single bone metastases 6 11
Multiple bone metastases 25 46
Multiple metastases 14 26
Unknown 10 18
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Weak Opioid (e.g. Codeine) 10 18
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*Simple - for example acetaminophen/paracetamol
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3.3.1. Pain Characteristics
The BPI results are shown in Figure 5. The median "pain right now" was 2 and the
median "average" pain was 4. The median "worst pain" score was 7. In the multiple
regression analysis, BPI worst pain was more strongly related to BPI interference
score than average pain. The coefficient for worst pain was 3.17 (SE 0.93, p=0.001)
and for average pain was 0.61 (SE 1.16, p=0.60).
The BPI scores were compared between those patients without, and those with,
breakthrough pain. The median (IQR) BPI average pain for those without and those
with breakthrough pain was 4 (3-5) and 5 (3-6) respectively. The median (IQR) BPI
worst pain for those without and those with breakthrough pain, was 5 (4-7) and 7 (4-
8) respectively. There was no statistically significant difference (at the p<0.05 level)
between the scores in these two groups.
Patients who had breakthrough pain had higher BPI interference scores than those
who did not have breakthrough pain (median (IQR); 35.0 (21.5-44.7) vs 18.5 (5.5-
26.7) respectively). This was statistically significant at p<0.01 level.
Figure 5 - Brief Pain Inventory - Cancer induced bone pain
Box and whisker plot representing the median value, with 50% of the data falling within the box
[Interquartile range]. The whiskers extend to the 5lh and 95,h percentiles.
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3.3.2. Breakthrough Pain
The results of the BTPQ are shown in Table 6. Forty-one patients (75%) had
breakthrough pain and completed the Breakthrough Pain Questionnaire.
The median (IQR) number of episodes of breakthrough pain over 24 hours was 4 (2-
8). The median severity of the breakthrough pain episodes was 8 (based on a 0-10
VAS). The speed of onset (time from being first aware of pain, to pain reaching its
peak) was less than 5 minutes in 33 patients (79%). Thirty-two patients (78%) had
breakthrough pain of less than 30 minutes duration. Eighteen patients (44%) had pain
which was unpredictable (including those patients who had onset of pain in less than
10 seconds).
Twenty patients (48%) had breakthrough pain which was of rapid onset (less than 5
minutes) and of short duration (less than 15 minutes).
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Table 6 - Breakthrough Pain Questionnaire - Cancer induced bone pain
Median IQR
Number of BTP episodes in 24 hours
4 2-8
Severity of BTP episodes
8 4-9














Rapid Onset (<5 Mins) & Short Duration (<15mins)
20 49
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3.4. Discussion
These data provide the first systematic characterization of CIBP which limits the
ability to compare these findings to studies published previously. Previous work has
examined breakthrough pain in cancer patients, however these studies included all
types of cancer pain (Portenoy et ah, 1999, Caraceni et al., 2004). By focussing on
CIBP as a single entity, clinically valuable information about general pain
characteristics and specific breakthrough pain characteristics in CIBP have been
determined.
3.4.1. Worst Pain
"Worst pain" correlated more strongly to the interference score of the BPI (effect on
general activity, mood, walking ability, work, relationships, sleep and enjoyment of
life) than "average pain". Previous work in CIBP has shown that worst pain
correlates with the interference scale of the BPI and our results support this (Harris et
ah, 2007, Shi et ah, 2009). These findings, however, also demonstrate that worst pain
is predictive of the interference score, over and above average pain, but not vice-
versa. Therefore if the worst pain score is known, there is nothing to be gained by
also knowing the average pain score. These findings have considerable clinical
significance when considering how best to assess the impact of CIBP on the
individual. Asking patients about their worst pain is more likely to give a meaningful
picture of the impact of their pain and its effect on their life as a whole. "What is
your worst pain?" is the crucial question in the assessment of a patient with CIBP.
The pain interference measures of the BPI have also been shown to correlate well
with QoL tools (Yun et al., 2004). It is arguable whether worst pain is a useful
surrogate measure of overall quality of life, however worst pain certainly correlates
with general function in CIBP.
3.4.2. Breakthrough Pain
The findings demonstrate that breakthrough pain is highly prevalent in patients with
CIBP. Seventy-five percent of the study population had breakthrough pain; pain that
flared up from a stable background level to a more intense pain. This finding is
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supported by the BPI data which demonstrated considerable differences between
pain now, average pain and worst pain scores. The difference in these scores was at
least 2 points (on a 0-10 VAS) which is clinically significant (Farrar et al., 2000).
Patients with breakthrough pain had higher BPI interference scores than those
without breakthrough pain. This would suggest that breakthrough pain impacts more
on day-to-day function than background pain. The psychological impact of
breakthrough pain highlights its importance to patients' physical and psychological
well-being and emphasizes the importance of asking the patient specifically about
their worst pain.
Previous research has also shown that the presence of breakthrough pain predicts
poor pain control,(Mercadante et al., 1992, Mercadante et al., 2002b) greater
functional impairment (Portenoy et al., 1999), higher levels of anxiety and
depression (Portenoy et al., 1999) and higher healthcare costs (Fortner et al., 2002).
This work has demonstrated that in CIBP, breakthrough pain is usually of short
duration and often less than 15mins. The majority of patients found their
breakthrough pain was rapid in onset and reached its peak intensity within 5 minutes.
Breakthrough pain which was unpredictable was present in 18 patients (44%).
As detailed in 2.4.4, in previous studies of cancer breakthrough pain more variable
characteristics have been reported, however these studies were in heterogeneous
groups (Portenoy and Hagen, 1990, Gomez-Batiste et al., 2002, Hwang et al., 2003).
Median durations of breakthrough pain have ranged from 15 minutes (Hwang et al.,
2003) to 30 minutes (Gomez-Batiste et al., 2002, Portenoy and Hagen, 1990).
Breakthrough pain has been reported as being unpredictable between 27% (Portenoy
and Hagen, 1990) and 58% (Hwang et al., 2003) of patients. The work presented
herein focuses exclusively on CIBP which enables a more meaningful analysis and
easier translation into patient care.
The finding in CIBP that breakthrough pain is often of sudden onset (less than 5
minutes) and short duration (less than 15 minutes), has several implications for
clinical practice and further research. Previous work has suggested that breakthrough
pain can be treated effectively using standard treatment regimens (Hwang et al.,
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2003). The established strategy of using IR morphine to manage breakthrough pain is
likely to be inadequate for this group of patients. IR oral morphine starts to provide
benefit, at best, at 30 minutes and takes 45-60 minutes to reach peak plasma
concentration. It has duration of action of 3-4 hours. As breakthrough pain in CIBP
has a more rapid onset and is of considerably shorter duration, it is likely that
patients will suffer significant opioid-related side-effects, as their pain resolves
without gaining effective analgesia for their breakthrough pain. In addition, the
dictum that patients take anticipatory analgesia prior to movement depends on a
predictable relationship between pain and movement. This is clearly not the case for
the significant number of patients with CIBP who have unpredictable breakthrough
pain. Also, for this strategy to be effective, patients have to anticipate incident pain to
allow time for their IR oral morphine to become effective.
In trying to mimic closely the time course of breakthrough pain, rapid onset, short
duration opioid preparations have been developed. However, the novel fentanyl
preparations still take 5-20 minutes to reach meaningful plasma levels, with duration
of action ranging from 2-3 hours (Portenoy et ah, 2006, Slatkin et al., 2007).
Alfentanil is an another short acting opioid that has been used for breakthrough pain
but there is limited evidence to support its use (Duncan, 2002). While this improved
opioid armamentarium may be useful for some patients, for those with rapid onset,
short duration breakthrough pain, this pain remains challenging.
Recent basic science work has increased the understanding of CIBP. In animal
models of CIBP, it has been reported that the mechanisms of CIBP are different to
those of inflammatory pain indicating that higher doses of opioids may be required to
achieve analgesia (Luger et al., 2002). The mechanisms for this are unclear but
alteration in mu opioid receptors and interaction with other receptors such as
transient receptor potential (TRP) family of ion channels, are likely to contribute to
this relative opioid resistance (Yamamoto et al., 2008, Niiyama et al., 2009). The
underlying pathophysiology of CIBP may differ from other pain states, necessitating
a fundamental change in the therapeutic approach to CIBP.
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3.4.3. Limitations
The study has several limitations. Patients who were in their last days of life or too
unwell to complete the study protocol were excluded from the study, but it seems
likely that these patients would have had a greater incidence of pain flares, consistent
with the finding that 86-89% of patients admitted to hospice services had
breakthrough pain (Fine and Busch, 1998). The sample size was small, although
various tumour types were included and the sample was likely to be representative of
a general oncology population.
The criterion used to identify those with breakthrough pain is open to criticism.
Patients had to have an increase of 2 or more points (on a 0-10 VAS) from their
background pain to their breakthrough pain. It was felt that any smaller differences in
pain scores may represent minor fluctuations in an otherwise stable pain and their
inclusion may reduce the clarity of our description of breakthrough pain associated
with CIBP.
In other studies, researchers have excluded patients who have not had regular
episodes of breakthrough pain, over the week prior to assessment, or who were not
on regular strong opioids (Hwang et al., 2003, Portenoy and Hagen, 1990, Portenoy
et al., 1999). These studies aimed to exclude patients who had only transitory flares
of pain, which were likely to settle spontaneously. As the included patients had pain
at sites of known bone disease, it was felt unlikely that their pain would settle
spontaneously. Excluding this group would miss of proportion of patients with
breakthrough pain. Some of the patients may have had analgesic end-of-dose failure
which may have resulted in unstable background analgesia and therefore a greater
amount of breakthrough pain.
In this study, as patients may have been taking analgesics these may have affected
the features of the breakthrough pain. In this patient group nobody was using rapid-
onset, short acting preparations. A proportion, however, was taking standard IR
opioids. In theory, if a patient had taken an IR opioid for their breakthrough pain this
may have limited the duration of their pain. It has been reported that IR opioids have
an onset of analgesic effect at 30 minutes with peak effect at 60 minutes (Bailey and
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Farley, 2006). Most patients had breakthrough pain of less than 30 minutes duration
so it is unlikely that IR opioids would have impacted on this.
3.5. Conclusion
The study provides the first systematic characterization of CIBP. It demonstrates that
breakthrough pain is highly prevalent in CIBP and is associated with significant
functional impairment. Breakthrough pain is often severe, rapid in onset and short in
duration. In view of this, current management strategies for treating CIBP are likely
to be inadequate for a sizeable number of patients. The increasing availability of
rapid-onset, short acting opioids may redress this for some patients, but this too
needs proper evaluation.
A single measure of pain is inadequate to describe the individual experience of
CIBP. However, if a single measure were to be used, "What is your worst pain?" is
the crucial question. Worst pain correlates more strongly with the effect of pain on
function than average pain scores.
Further, larger studies are needed to determine the frequency and intensity of CIBP
in the broader cancer population.
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Chapter 4. A Systematic Review of Cancer Pain and
Depression
4.1. Introduction
Pain and depression are both common in cancer patients and the relationship between
these symptoms has been of increasing interest (Caraceni and Portenoy, 1999, Lloyd-
Williams et al., 2004). The issue of a possible interdependent association between
these two symptoms has been raised. Epidemiological studies have shown that
depression and pain are often present together (Bair et al., 2004). There is also
physiological evidence to support this theory. Imaging studies have shown that the
areas in the cerebellar cortex which process pain are also implicated in depression
(Giesecke et al., 2005, Smith et al., 2002).
Pain in cancer patients is affected by many variables including cancer stage, extent of
disease and treatment (Andersen and Sjogren, 1998). A single point prevalence
survey, published in 1999 on behalf of IASP demonstrated that approximately 90%
of patients with cancer experienced pain (Caraceni and Portenoy, 1999). Despite the
high prevalence of pain amongst cancer sufferers, 80% of cancer pain can normally
be controlled if simple guidelines are followed (Ventafridda et al., 1987). It follows
that approximately 20% of patients with cancer pain will not achieve adequate
analgesia with standard treatments.
Depression is the most common psychiatric condition in cancer, occurring in
approximately one quarter of patients with advanced cancer (Lloyd-Williams et al.,
2004). It has been suggested that depression is four times more common in cancer
patients than in the general population and is often under-diagnosed (Derogatis et al.,
1983, Block, 2000).
Pain and depression have been examined in the non-malignant setting. A
randomised controlled trial, (the ARTIST study) published in 2000 demonstrated that
pain is a strong predictor of depression (Bair et al., 2004). Patients with severe pain
were four times less likely to respond to depression treatment. As pain decreased, a
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response to treatment for depression increased. This is one of the few studies that
illustrate how the presence of pain affects response to depression treatment.
In chronic medical illness, the association of depression and anxiety with physical
symptom burden, has been studied in a systematic review (Katon et al., 2007). It
concluded that physical symptoms (such as pain) were associated with depression
and anxiety. It has also been shown that an improvement in depressive symptoms is
associated with an improvement in somatic symptoms (Borson et al., 1992, Lin et al.,
2003b, Bair et al., 2003).
Less is known regarding the relationship between pain and depression in the
oncological setting. Although the epidemiology and treatment of cancer pain and
depression have been studied previously, the relationship between them has not been
examined (Carr et al., 2002). A systematic review examining the relationship
between these two symptoms has not been carried out previously.
Thus the aim of this systematic review was to assess the evidence for a relationship
between cancer pain and depression.
4.2. Methods
Ethical approval was not required for this systematic review. The following
databases were searched electronically: Medline (1950-2007), Embase (1988-2007),
CINAHL (1982-2007) and the Cochrane Database of Systematic Reviews (Issue 2
2007). In addition, the following journals were searched manually: Palliative
Medicine, Journal of Pain and Symptom Management, Progress in Palliative Care
and the European Journal of Palliative Care.
The following search terms were used: "cancer" AND "pain" AND "depression",
using MeSH terms; all subheadings were included. Results were limited to English
language journals and studies involving humans. Due to the broad search
terminology a large number of results was obtained. The titles of all the articles
retrieved were subsequently reviewed and the abstracts of all the articles deemed
relevant, in accordance with inclusion criteria, were retrieved in whole.
Subsequently, all papers were reviewed independently by two authors. These were
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analysed to assess quality, using a pre-determined schedule (Appendix 1) which was
based on the Scottish Intercollegiate Guidelines Network (SIGN) appraisal guideline
(SIGN, Edinburgh).
4.2.1. Inclusion Criteria
Studies were included if the sample examined cancer patients of any tumour type, at
any stage of the disease. Papers that included cancer in addition to other medical
conditions were eligible. In addition, studies had to define depression using a
recognised tool. Some studies only examined distress or mood per se, however, if
depression was studied as a component of this, then these studies were eligible.
Eligible studies also had to assess pain. This was defined using an assessment tool
which varied according to individual studies. Studies were required to explore the
relationship between the two variables, pain and depression. Systematic reviews
were deemed eligible.
4.2.2. Exclusion Criteria
Studies were excluded when they did not meet all inclusion criteria. Thus if studies
did not include a cancer population, define depression and define pain, they were not
eligible for this review. Studies which did not present original material were
excluded, as were critical and narrative reviews (systematic reviews were eligible).
Those articles examining pain and depression in non-malignant disease were also
excluded as were papers which analysed distress or other psychiatric symptoms but
did not define depression.
4.3. Results
The literature search retrieved 892 articles and the review process is shown in Figure
6. The titles of these were reviewed and, if deemed potentially appropriate, selected
for further analysis. This resulted in 167 articles, which were reviewed in greater
detail and, once again if potentially relevant, were selected for further analysis.
Forty-one articles were subsequently reviewed independently by two of the authors.
Consensus was agreed on 28 articles without discussion. Further debate among the
authors led to agreement regarding all articles. Fourteen articles were deemed
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appropriate for inclusion in this review as shown in Table 7. The date of the last
literature search was 19th June 2007.












<=> 725 articles excluded (not
relevant)
126 articles excluded (poor
design)
14 articles included 27 articles excluded
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Lin CC et al (Lin et al., 2003a) 484 POMS BPI
Heim and Oei (Heim and Oei,
1993)
47 BDI MPQ










Chen et al(Chen et al., 2000) 203 HADS VAS




Margetic et al., 2005)
115 CES-D VAS
Kelsen et al (Kelsen et al.,
1995)
130 BDI MPAC
Sist et al(Sist et al., 1998) 190 BDI MPQ
Mystakidou et al (Mystakidou
et al., 2007b)
82 BDI BPI
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Of the excluded articles, 18 were cross-sectional studies and were excluded on the
grounds that pain and/or depression were not defined, or a relationship between these
two entities was not examined. Excluded articles also included three reviews, two
qualitative studies, one crossover trial, one intervention study, one consensus
statement and one paper examining views of caregivers. All of these did not meet the
inclusion criteria. A large number of excluded studies failed to define depression and
instead looked at general areas such as "distress" and "suffering" of which clear
boundaries and definition are lacking. No systematic reviews were found.
Of the included studies, the study design was categorized, based on
recommendations described by Stephenson and Babiker (Stephenson and Babiker,
2000). All included studies were of a prospective design. Twelve studies were cross-
sectional in design whilst two were cohort studies. Methodology varied among the
studies. Some studies divided subjects into those with and those without pain. This
allowed comparison between the groups. In other studies all patients had pain.
A selection of assessment tools for both depression and pain were utilised Table 7.
Measurements of depression included the Hospital Anxiety and Depression Scale
(HADS), Centre for Epidemiological Studies Depression Scale (CES-D), Profile of
Mood States (POMS), Beck Depression Inventory (BDI), Structured Clinical
Interview for Depression (SCID), Endicott Criteria and the Brief Symptom Inventory
(BSI - where depression was measured as a component). Pain was assessed using a
variety of assessment tools. These included the McGill Pain Questionnaire (MPQ),
the Brief Pain Inventory (BPI), numerical rating scales, the Memorial Pain
Assessment Card (MPAC) and Visual Analogue Scores (VAS). These pain
assessment tools are not designed to assess prevalence and instead measure features
of pain such as intensity and descriptors. However, by having a score greater than
zero on any one of these tools, it is reasonable to conclude that these patients had
pain.
Only four studies had the methodology to allow a combined prevalence of pain and
depression to be calculated as shown in Table 8. In three of these studies, the entire
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patient sample had pain and thus the prevalence of depression could be deduced. In
the remaining study, the authors quoted the combined prevalence. In those patients
with pain, the mean prevalence of depression was 36.5% (range 22.1 - 49). This
prevalence must still be interpreted with caution as different assessment tools were
used. A statistical association between pain and depression was demonstrated in
some of the studies (Table 9).
Table 8 - Prevalence of depression in patients with cancer pain.
Reference Depression Assessment tool Depression Prevalence (%)
Sist et al(Sist et al., 1998) BDI 22.1




SCID + Endicott 49.0
Spiegel et al(Spiegel et al.,
1994)
SCID 46.0
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Table 9 - Studies where a statistical association is demonstrated.
Reference Pain & depression - statistical
association
Heim and Oei(Heim F=3.892***
and Oei, 1993)
P=0.05






Chen et al (Chen et al., t=7.00**
2000)
p<0.001
Glover et al (Glover et t=2.52
al., 1995)
P<0.01
Aukst-Margetic et al U=1089*
(Aukst-Margetic et al.,
2005) P=0.009
Kelsen et al (Kelsen et 0.3575*****
al., 1995)
P=0.001
Sist et al (Sist et al., Q J4]******
1998)
P<0.05
Zimmerman et al Q ] *****
(Zimmerman et al.,
1996) P<0.01
*=Mann Whitney test **=t-test ***=univariate F tests
****=Spearman correlation coefficients
*****=Pearson correlations ******=ANOVA two analysis of variants
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4.4. Discussion
None of the included studies were designed to examine a causal relationship between
pain and depression, thus causality cannot be determined. Due to the methodology
used in individual studies and variation in classification of depression and pain,
meta-analysis of included studies was not possible. Thus common themes from the
studies were examined.
4.4.1. Epidemiology of Cancer Pain and Depression
One of the main difficulties in ascertaining accurately the prevalence of depression in
patients with cancer pain, lies in the variety of assessment tools used to define
depression. As discussed, inferences regarding the combined prevalence of pain and
depression could only be drawn from four studies (Table 8). The prevalence of
depression seemed to vary according to the assessment tools used. Depression was
least prevalent when using the BDI whilst studies using the SCID had a greater
prevalence of depression.
The remaining studies did not allow calculation of the prevalence of co-existing
depression and pain, however other conclusions were drawn by the authors.
Depression was more common in those patients with increased pain severity and this
group had a lower prevalence of major depression than those where pain was less
severe (Spiegel et al., 1994). The authors suggested that pain caused depression and
postulated that under-treatment of pain may cause increased suffering and
depression.
Other factors such as sex and age are considerations. It has been shown that women
are more likely to be depressed than men (Mystakidou et al., 2006). Older patients
with cancer pain are more likely to be depressed than younger patients (Mystakidou
et al., 2006). This association has, however, been refuted by other research work,
including a recently-published systematic review examining age-related patterns
(Williamson and Schulz, 1995, Gagliese et al., 2007).
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4.4.2. Relationship between pain characteristics and depression.
Themes have emerged suggesting relationships between specific pain characteristics
and depression. It has been shown that, as pain increased (as measured by all
components of the MPAC), so did depressive symptoms (Kelsen et ah, 1995). Many
of the studies used detailed pain assessment tools allowing detailed analysis of
specific components of pain and their relationship to depression.
4.4.2.1. Pain Intensity
Pain intensity correlated positively with depression (to levels of statistical
significance p<0.05) (Kelsen et al., 1995, Sist et ah, 1998, Ciaramella and Poli,
2001). Worst pain intensity also correlated positively with depression (to levels of
statistical significance) (Glover et ah, 1995). "Current pain intensity" correlated
significantly with mood on POMS (Profile of Mood States), but this did not reach
statistical significance on the CES-D (Spiegel et ah, 1994). Patients who were
depressed reported a higher intensity of pain than non-depressed patients (Sist et ah,
1998). Increasing pain was associated with increased levels of depression (Spiegel et
ah, 1994). Sze et al examined whether pain intensity and disability differ in
depressed patients (Sze et ah, 2000). They showed no difference in the nature and
severity of pain between depressed and non-depressed cancer patients. This did not
reach statistical significance (p =0.18), perhaps due in part to the small sample size
of 70 patients.
4.4.2.2. Pain Descriptors
When specific items on the MPQ were explored, patterns seemed to emerge. Patients
who were depressed scored higher on the affective pain intensity scores and the
affective pain descriptors, than their non-depressed counterparts (Sist et ah, 1998).
Words in the "punishment" and "tension" sections were more likely to be chosen by
those patients with pain and depression. It was also shown that pain interference
items such as "worst pain" and "enjoyment of life" (measured on the BPI) correlated
significantly with depression (Mystakidou et ah, 2007b).
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4.4.2.3. Pain Perception
Patients' perception of their pain differed between those with depression and those
without. Aukst-Margetic et al used a visual analogue score to assess pain and found a
statistical difference (u=1089, p=0.009) in pain perception between depressed and
non-depressed groups (Aukst-Margetic et al., 2005).
4.4.2.4. Pain Duration
It has been shown that the longer the duration of pain, the higher the risk of
depression (Kelsen et al., 1995, Glover et al., 1995). It has also been suggested that
as pain increased over time, so did depressed affect, but this was not statistically
significant (Williamson and Schulz, 1995).
4.4.3. Is there an association between pain and depression?
Although it is reasonable to conclude that depression and pain are both highly
prevalent in cancer patients, it does not necessary follow that these are related. Some
of the studies included in this systematic review explore the relationship, by
analysing the prevalence of depression in a cohort of patients with and without pain.
One study examined patients with prostate cancer and showed that those who
suffered from pain were more depressed than those who were pain-free (Heim and
Oei, 1993). All patients with metastatic disease reported pain and there was a
statistically significant difference in prevalence of depression between those with and
those without pain. This finding was supported in other studies, showing that
patients with pain had a higher prevalence of depression (Chen et al., 2000, Glover et
al., 1995, Ciaramella and Poli, 2001, Aukst-Margetic et al., 2005). Such studies used
specifically-designed tools to identify depression.
When tools that are less sensitive at measuring depression are used, it is not
surprising that fewer inferences can be drawn. Where depression was assessed as part
of the BSI, it was shown that whilst patients with pain had more psychological
symptoms, this did not reach statistical significance when depression was analysed
(Zimmerman et al., 1996). Another study of approximately 500 patients revealed
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that patients with pain had higher levels of overall mood disturbance, but did not
have statistically-higher levels of depression (Lin et al., 2003a).
Due to the variety of assessment tools and criteria used to define pain and depression
in the included studies, direct comparison and amalgamation of data is not possible.
Yet it has been demonstrated that there are statistically significant associations
between specific pain characteristics and depression. Furthermore, some studies have
shown a general association between pain and depression (Table 9). However, the
evidence available is not sufficient to support a causal relationship between pain and
depression.
4.5. Conclusion
Psychological symptoms (depression, anxiety, somatisation) are more prevalent in
cancer patients with pain than those without (Zimmerman et al., 1996). This
systematic review has demonstrated that both pain and depression are highly
prevalent in cancer patients. It is also reasonable to conclude that specific features of
pain (such as intensity or effect on enjoyment of life) are related to depression. The
question remains as to whether these two entities are interdependent. It would seem
reasonable to conclude that pain, depression and anxiety are closely linked, given
what we know about their common central pathways and neuropharmacology (Remy
et al., 2003). The evidence presented does suggest an association, but is insufficient
to assign a causal relationship.
Until a firm evidence-base can be established, the question of a bidirectional
relationship between cancer pain and depression remains unresolved, with
management based on individual assessment. Both pain and depression have
significant clinical impact. It is important, therefore, in further studies to establish
whether or not there is a causal relationship. This would have implications for the
way individual patient management is approached. To provide further weight to the
hypothesis that pain and depression may be connected, different study methodology
is needed. Such studies require to be of a longitudinal design. Uniformly-agreed
assessment tools will also allow comparisons to be made between studies. Through
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these, the theoretical interdependent relationship between cancer pain and depression
could be studied. This would be an important step in the research agenda.
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Chapter 5. A Longitudinal Study of Cancer Pain and
Depression
5.1. Introduction
Pain and depression are common symptoms in cancer patients. It has been reported
that 90% of cancer patients experience pain (Caraceni and Portenoy, 1999).
Depression occurs in approximately 25% of patients with cancer and is the most
common psychiatric condition in cancer patients (Derogatis et ah, 1983, Lloyd-
Williams et ah, 2004). As pain and depression are both common in cancer patients,
the possibility of an interdependent relationship between these two symptoms has
been suggested. It has also been suggested that these symptoms may form a symptom
cluster in combination with fatigue (NIH, 2003). Although pain and depression are
often present together in cancer patients there is little evidence to support that these
symptoms are related (NIH, 2003, Glover et ah, 1995).
In addition to depression, the term "distress" has become increasingly commonplace
when discussing psychological morbidity in cancer patients. Depression and distress
are often used interchangeably thus it is difficult to define what distress is and its
prevalence. The National Comprehensive Cancer Network (NCCN) defines distress
as:
"a multi-determined unpleasant emotional experience of a psychological
(cognitive, behavioural, emotional), social, and/or spiritual nature that may
interfere with the ability to cope effectively with cancer, its physical
symptoms and its treatment. Distress extends along a continuum, ranging
from common normal feelings of vulnerability, sadness and fears to problems
that can become disabling, such as depression, anxiety, panic, social isolation,
and spiritual crisis" (NCCN, 2002).
As this definition may include a vast number of cancer patients the term "emotional
distress" has also been used. It is helpful as patients may have symptom patterns that
do not fit neatly into a diagnosis of anxiety or depression, however still have a
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psychological symptom burden (Costantini et al., 1999). Emotional distress is an
important part of the spectrum of psychological symptoms that can affect cancer
patients.
A discussed in chapter 4, a systematic review has examined the evidence for a link
between pain and depression (Laird et al., 2008). In patients with pain the mean
prevalence of depression was 36.5%, although this was dependent on the assessment
tool used. Pain intensity has also been shown to correlate with depression (Kelsen et
al., 1995, Ciaramella and Poli, 2001, Sist et al., 1998). It has also been shown that the
longer duration of pain, the higher the risk of depression (Glover et al., 1995, Kelsen
et al., 1995).
It is reasonable to conclude that pain and depression are highly prevalent in cancer
and that some pain features may be associated with depression. Despite this, previous
work was not designed to assess a causal link and whilst this work does suggest an
association, there is insufficient evidence to support an interdependent relationship
(Laird et al., 2008).
As both pain and depression can have a significant clinical impact, it is important to
develop a greater understanding of the relationship between these symptoms. This
would impact on the management of these symptoms in a clinical setting and the way
individual patient management is addressed.
Examining the relationship between pain and depression poses several
methodological challenges. In the cancer setting, symptomatology can often vary on
a day-to-day basis. The use of treatments targeting pain and depression can render
the assessment of these symptoms in a controlled setting, challenging. It has been
suggested that any research conducted to assess a possible link between these
symptoms should be of a longitudinal design (Laird et al., 2008). By treating one of
these symptoms in isolation, the effect on the other could be assessed.
In the cancer setting, there have been no previous studies which have examined the
relationship between pain and depression, using a longitudinal methodology. The
aim of this longitudinal study, therefore, was to assess depression and distress, when
pain is treated.
A longitudinal study of cancer pain and depression 56
5.2. Methods
5.2.1. Overview
The study took the form of a secondary analysis of two clinical studies datasets. The
datasets were combined to allow an analysis to be undertaken. These two studies
examined the effect of radiotherapy on CIBP. In both studies, patients received
palliative radiotherapy for CIBP. Assessments of pain and depression were
performed at study baseline and endpoint. One of the studies used an investigational
medicinal product (IMP) or placebo, in addition to radiotherapy. The IMP was
pregabalin and its role as an adjuvant analgesic for CIBP was being investigated. The
second study was a clinical characterization study with no additional intervention.
As this was an analysis of existing data, no additional ethical approval was required.
The original studies had appropriate ethical approval and were conducted in
accordance with the International Committee for Harmonisation, Good Clinical
Practice and the Helsinki Declaration.
5.2.2. Inclusion Criteria
Patients, with metastatic cancer and radiologically confirmed bone metastases,
attending one of two regional oncology centres in the United Kingdom, were
included. All patients had CIBP with a worst pain score (at the site of CIBP) of > 4
(on a 0-10 VAS). All patients were, at baseline, about to receive palliative
radiotherapy for CIBP. Patients had a life expectancy of greater than two months.
Patients were allowed to take standard analgesia (including strong opioids) for the
duration of the studies and doses were increased or decreased as required for
symptom control. Patients were also allowed to take adjuvant analgesics or
antidepressant medication.
5.2.3. Exclusion Criteria
Patients felt to be in the last two months of their lives or who were unlikely to be
able to complete the study protocol due to their clinical condition, were excluded. In
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addition, patients who had did not have CIBP and were not due to receive palliative
radiotherapy were excluded.
5.2.4. Procedures
Written informed consent was obtained. Demographics and information concerning
the patient's underlying malignancy was gathered from their medical records.
Two structured interviews were conducted with each patient; at study baseline (prior
to radiotherapy) and study endpoint (four to eight weeks later).
During these interviews, pain and depression were assessed using validated
assessment tools. Types and doses of analgesic drugs taken in the preceding 24 hours
were recorded. For ease of comparison, opioid doses were converted to oral
morphine equivalents (Morphine equivalent daily dose - MEDD) using a recognised
and accepted conversion table (Fallon et ah, 2009). Anti-depressant medication and
any dose change in the previous four weeks (which could ,in theory, have affected
mood) was documented. Some patients were taking tricyclic antidepressants (e.g.
amitriptyline) for neuropathic pain. This was only classified as an anti-depressant if
the dose per day was greater than 75mg.
5.2.5. Assessment Tools
All patients completed the Brief Pain Inventory (BPI) and the Hospital Anxiety and
Depression Scale (HADS).
5.2.5.1. Brief Pain Inventory
The BPI has been discussed in 2.2.4.1. An improvement in the total BPI score of
>30% was defined as being a clinically significant improvement in pain. Patients
whose total BPI score fell by 30% or more were classified as responders. Those
whose pain did not fall by 30% were classified as non-responders.
5.2.5.2. Hospital Anxiety and Depression Scale
The HADS (Appendix 1) was developed as an assessment tool for depression and
anxiety in hospital outpatients (Zigmond and Snaith, 1983). It has been used in
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cancer patients and has been validated in this population (Le Fevre et ah, 1999). The
HADS consists of two subscales - an anxiety subscale and a depression subscale,
which total 14 questions. Each question can score between 0 - 3 on a scale (the
higher the score the greater the symptom) and a maximum score of 42 is possible.
The subscales can be analysed either independently or a combined score can be
calculated. The combined score is the most widely used clinically and it has been
shown that combining the anxiety and depression scores is predictive of depression,
as opposed to using the depression score alone (Le Fevre et al., 1999, Walker et ah,
2007). A combined score of > 15 has been suggested as a cut-off for major
depressive disorder (MDD) and therefore was used for the study (Walker et al.,
2007). This cut-off score was based on a comparison study with the Structured
Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders
(Walker et al., 2007, APA, 1994).
A combined HADS score of > 10 been suggested as a valid measure of emotional
distress and this cut-off was used in our study (Razavi et al., 1992, Costantini et al.,
1999, Walker et al., 2007). For the sake of brevity, patients whose HADS score was
> 15 are referred to as "depressed" and those whose HADS score was < 15 are
referred to as "not-depressed". Patients whose HADS score was > 10 are referred to
as "distressed" and those whose HADS score was < 10 are referred to as "not-
distressed".
5.2.6. Statistics and Analysis
Patient demographics were summarised using proportions, and means and standard
deviations (SDs). Analysis was undertaken of all patients. These were divided into
groups whose pain had improved during the course of the study (responders) and
those who had no improvement (non-responders). The baseline and endpoint data for
the BPI and the HADS were summarised using medians and inter-quartile ranges
(IQRs).
Due to the small sample size, a Fishers exact test was performed on these data. An
initial analysis was done assessing the relative proportions of depressed and non-
depressed patients in each group (responders and non-responders). Further analysis
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taking into account patients' baseline characteristics was performed. An analysis of
covariance was done to assess the change in HADS score between responders and
non-responders.
5.3. Results
The patient demographics are shown in Table 10. Sixty-nine patients were recruited.
Forty (58%) patients were male and the mean age was 67.1 years (SD 10.4, range 38-
88). Breast and prostate were the most common tumour sites. All patients received
radiotherapy for CIBP following the initial interview.
Sixty two (90%) patients were receiving strong opioids at study baseline. The mean
MEDD at baseline was 76 mg (range 0-800mg). Fifty nine (86%) patients were
receiving strong opioids at study endpoint. The mean MEDD at endpoint was 90mg
(range 0-600mg). Patients were taking various adjuvant analgesics including
NSAIDs, amitriptyline, gabapentin and lidocaine patches. Where amitriptyline was
used as an adjuvant analgesic for neuropathic pain, the dose was 75mg per day or
less, and unlikely to exert any antidepressant effect. No other antidepressants were
used as adjuvant analgesics. Two patients were taking antidepressants at study
baseline (Fluoxetine and Losepramine). The doses of these had not altered in the
previous four weeks. At study endpoint the same two patients were on
antidepressants, however in one patient this had changed from Losepramine to
Mirtazapine.
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5.3.1. Hospital Anxiety and Depression Scale
The baseline and endpoint HADS scores of responders and non-responders are
shown in Table 11. Both groups were similar at baseline. No statistically significant
difference was observed between "responder" status and the categorised depression
baseline score (at the p>0.05 level).In the non-responder group the HADS score
increased by 3 points whereas in the responder group, this fell by 4 points.





















14) 3(1-4) 3 (2-6) 6(4-11)
5.3.2. Brief Pain Inventory
The total BPI score and the interference component of the BPI score were assessed at
baseline and endpoint. The results are displayed in Table 12. At baseline, the BPI
total and interference scores in both groups, were similarly matched. There was an
increase in the median total score and interference score in the non-responders. In
those whose pain did respond, there was a decrease in the median total score and
interference score.
Table 12 - Baseline and endpoint BPI
Baseline Endpoint




(IQR) 52(38-61) 30(23-40) 55(39-65) 33(23-43)
Responders
Median
(IQR) 49(34-62) 30(19-40) 11 (2-20) 4(0-13)
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5.3.3. Relationship between pain and depression
The relationship between pain and depression was assessed. Those patients whose
HADS score was > 15, were defined as being depressed. When considering the
depression as a qualitative variable, the cross-tabulation is observed as shown in
Table 13.




Non-Responders 11 (58%) 8 (42%)
Responders 43 (86%) 7 (14%)
Of the responders 86% of patients are not depressed at endpoint, compared with 58%
in the non-responder subset. There is a statistically significant difference (p =
0.0203) in the depression status between the non-responders and the responders.
However, these results do not adjust for the baseline depressive status of the patient.
When taking into account patients' baseline HADS status, the cross-tabulation is
observed as shown in Table 14.














Non-Responders 9 (69%) 4 (31%) 2 (33%) 4 (67%)
Responders 35 (92%) 3 (8%) 8 (67%) 4 (33%)
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Of those patients who are not depressed at baseline, most of them remain not
depressed. Of the 38 patients whose pain improved (responders), 35(92%) remain
depression-free. Of the 13 patients whose pain did not improve, 9 (69%) remained
depression-free. The Fishers exact test p-value for this was 0.06, suggesting there
was no association between responder status and depressive status at the 5% level.
Of those patients who were depressed at baseline; in the 12 patients whose pain
improved, 8 (67%) had a change in their depression in status from depressed to non-
depressed. Of the 6 patients whose pain did not improve, only 2 (33%) had a change
in their depression status from depressed to non-depressed. The Fishers Exact Test p-
value was 0.32 suggesting that there was no association between these groups at the
5% level.
5.3.4. Emotional Distress
The relationship between pain and emotional distress was assessed. Those patients
who had a HADS score >10 were defined as being emotionally distressed. When
considering the depression as a qualitative variable the cross-tabulation is observed
as shown in Table 15.





Non-Responders 6 (32%) 13 (68%)
Responders 36 (72%) 14 (28%)
Of the "responders" 72% of patients were not distressed at endpoint, compared with
31% in the "non-responder" subset. A Fishers exact test of association concludes a
statistically significant association with a p-value of 0.0048. In other words there was
a statistically significant association between the pain-responder status and emotional
distress.
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When taking into account patients' baseline HADS scores as an indicator of distress,
the following cross tabulation is observed as shown in Table 16.
Table 16 - Pain and distress - adjusted for baseline distress status
NOT Distressed at
BASELINE (n=31)









Non-Responders 4 (57%) 3 (43%) 2(17%) 10 (83%)
Responders 23 (96%) 1 (4%) 13 (50%) 13 (50%)
Of those patients who were not distressed at baseline, most of them remained not
distressed. Of the 24 patients whose pain improved (responders), 23(96%) remained
distress-free. Of the 7 patients whose pain did not improve, 4 (58%) remained
distress-free. The Fishers exact test p-value for this was 0.02 suggesting these was a
statistically significant association between pain-responder status and emotional
distress at the 5% level.
Of those patients who were distressed at baseline; in the 26 patients whose pain
improved, 13 (50%) changed from distressed to non-distressed. Of the 12 patients
whose pain did not improve, only 2 (17%) had a change in their distress status from
distressed to non-distressed. The Fishers exact test p-value was 0.07 suggesting the
observed association between the two groups was not statistically significant at the
5% level.
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5.3.5. Effect on HADS score
The effect of pain on the HADS score is shown in Table 17.
Table 17 - Effect of pain on HADS score
Mean change (S.D.)* minimum, maximum
Non-Responders (n=19) 0.73 (5.36) -10, 8
Responders (n=50) -2.52 (5.47) -16, 18
*Standard Deviation
Responders are on average, dropping 2 points on the HADS score between baseline
and endpoint. The non-responders are on average increasing 1 point on the HADS
between baseline and endpoint. An analysis of covariance shows a statistically
significant difference between the two response categories. An F-test with a p-value
of 0.006 with an estimate difference in LS (Least Squared) means = 4.6. This is
statistically significant in favour of those whose pain improved, (responders)
reducing the HADS score. In conclusion an improvement in pain will, on average,
reduce the HADS score.
5.4. Discussion
The study examines the natural evolution of depression, distress and pain in cancer
patients. Treating pain reduces the HADS score whereas if pain does not improve,
the HADS score increases. There is a trend towards an improvement in depression
score in those in whom pain is reduced, however this was not statistically significant.
When pain improves so does distress. These findings suggest an association between
depression, emotional distress and pain. When pain is treated, depression and distress
appear to improve which suggests a possible unidirectional relationship between pain
and depression/distress. This would support the theory that depression and distress
may be influenced by pain, but is not sufficient to support the reverse, i.e. that pain is
influenced by depression and distress.
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As similar studies in a cancer population are lacking, a comparison with other work
is difficult. In the non-cancer setting, pain and depression have been examined and in
this setting depression seems to influence pain (Bair et al., 2004). Some work has
been done (as discussed in Chapter 4) but none of these studies employed the
necessary longitudinal design required to assess the relationship between pain and
depression.
This study would suggest that treating pain may modify depression and distress. This
may be due to the impact of one symptom on another clinically, through a common
underlying pathophysiological process or a combination of these as discussed in
1.3.1. In cases where pain and depression co-exist, it could be argued that treating
pain may improve depression, negating the need for anti-depressant therapy in some
cases. Emotional distress may also improve if pain is managed sufficiently well.
5.4.1. Limitations
One of the main problems when assessing depression is in the definition. The HADS
is a screening tool for depression and not a diagnostic tool. In this study, major
depressive disorder was defined as being a combined HADS score of > 15. This cut¬
off point has been shown to be a reasonable, sensitive and specific guide when
screening for major depressive disorder (Walker et al., 2007). However, this cut-off
point may have missed some cases ofMDD.
The HADS has been used as a surrogate marker of distress in many studies (Razavi
et al., 1992, Costantini et al., 1999, Walker et al., 2007). The specific HADS cut-off
point used to assess for emotional distress is open to debate. A score of > 10 but <15
was used in this study, however scores of > 15 have been used and been suggestive
of clinically significant emotional distress (Ibbotson et al., 1994). It could be argued
that patients defined as having emotional distress in this study would not been
classified as having clinically significant emotional distress when higher cut-offs are
used. A degree of pragmatism is needed, as such definitions are open to cultural
interpretation and can also vary in severity based on underlying psychological coping
mechanisms.
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The study population was highly selective, consisting of oncology outpatients with a
limited group of primary tumour sites. All patients received radiotherapy at baseline
as part of a larger study and all patients were in a clinical trial setting. This gold
standard treatment for CIBP allowed prediction of at least a 50% reduction in pain, in
50% of patients.
Patients in a clinical trial are under close medical and nursing supervision and this
may have had some impact on depression and distress. Furthermore, the majority of
patients were taking strong opioids, suggesting that this group may have a higher
pain burden or may have been in regular contact with primary or palliative care. In
turn, this may have been therapeutic in improving depression. It is difficult to
minimize the effect of such confounding variables within a research context. It is
important to emphasize, however, that despite the homogeneous nature of the study
population, a proportion of patients failed to achieve an improvement in pain control,
depression and distress.
Combining two datasets, such as was done here, has some limitations. In particular a
proportion of patients were in a trial of an IMP (pregabalin) and may have been
taking this (half of patients would have been on placebo). Pregabalin may have had
mood altering effects and this may have impacted on HADS scores. This highlights
the difficulties in combining two datasets, as although the populations were similar in
many ways, there were some particular differences which may have affected
findings.
One of the main reasons that limited conclusions can be drawn from these results is
the small sample size. Fifty-one (74%) patients were not depressed at baseline
meaning the proportion of depressed patients in the study was very small. As
mentioned previously, the population was homogeneous, however approximately
25% of patients were depressed. This is in keeping with other studies in the cancer
population (Derogatis et ah, 1983, Lloyd-Williams et ah, 2004).
5.5. Conclusion
The study is the first to examine the natural evolution of depression and emotional
distress in patients where only pain is treated. These findings suggest that depression
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and distress may influenced by pain. Treating pain decreases the HADS score,
whereas if pain does not improve, the HADS score increases.
Further work is needed to assess the relationship between pain, depression and
distress. Such research should take place in the broader cancer population and with a
larger sample size. A more robust method of diagnosing depression, such as a SCID,
should also be used to improve the sensitivity and specificity of diagnosing
depression. The impact of depression and distress on pain also requires to be
assessed. If future work supports associations between these, it may have
considerable implications on the management of these common and challenging
symptoms.
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Chapter 6. Cancer Pain and its Relationship to
Systemic Inflammation
6.1. Introduction
Systemic inflammation is part of the complex pain jigsaw. As cancer progresses,
patients tend to experience more pain and whilst in a simplistic way, this may be due
to an increase in the symptom burden, it may also be due to other mechanisms such
as systemic inflammation.
It has been widely accepted, that there is a relationship between cancer and systemic
inflammation. Systemic inflammation has been shown to predispose to certain
tumour types,(McKay et al., 2008) has been implicated in oncogenic mutations and is
present in experimental animal models of tumour development (Mantovani et al.,
2008). Systemic inflammation can also be a result of cancer. Targeting systemic
inflammation through various therapies has been shown to reduce cancer risk and
cancer spread (Mantovani et al., 2008).
6.1.1. Pain and inflammation
Pain has also been shown to be related to inflammation. This is not a new concept as
the four key components of inflammation were first described as calor (heat), dolor
(pain), rubor (redness) and tumour (swelling). In recent years the relationship
between pain and systemic inflammation has been widely accepted both as a
mechanism and as a possible therapeutic target, for treating pain (Zhang and An,
2007).
6.1.2. C-reactive Protein
Systemic inflammation can be assessed using C-reactive protein (CRP). This
biomarker has been used to demonstrate systemic inflammation in both hormone
dependent and hormone independent cancer (Falconer et al., 1995, O'Gorman et al.,
1998, Crumley et al., 2006). CRP is an acute-phase plasma protein, manufactured in
the liver (Gaw et al., 1995, Pepys and Hirschfield, 2003). CRP concentrations rise
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dramatically during inflammation and remain elevated, whilst the underlying
inflammatory process remains active. As the half-life of CRP is 19 hours, levels only
remain elevated if there is ongoing stimulus for production, usually underlying
inflammation or malignancy (Vigushin et ah, 1993).
6.1.3. lnterleukin-6
CRP is produced under the control of interleukin 6 (IL-6). IL-6 acts as a pro¬
inflammatory cytokine and has multiple roles although is a critical mediator of
inflammation and the pro-inflammatory cytokine response (Hodge et al., 2005). It
has been demonstrated in cancer patients that IL-6 is independently associated with
CRP and that CRP, is a useful surrogate measure of IL-6 (McKeown et ah, 2004,
Ramsey et ah, 2006). It is, therefore, reasonable to conclude that as CRP production
is dependent on IL-6, CRP concentrations are directly related to IL-6. Thus CRP
serves as a biomarker for systemic inflammation in general, but also acts as a
measure of IL-6.
6.1.4. Aim
The aim of this study was to assess the relationship between pain and systemic
inflammation (using CRP as a measure of IL-6) in a cohort of cancer patients.
6.2. Methods
6.2.1. Overview
Secondary analysis was undertaken of two existing clinical trial datasets. The two
clinical trials were as follows:
Trial 1 - Double-blind, placebo-controlled, randomised study of eicosapentaenoic
acid (EPA) diester in patients with cancer cachexia (Fearon et ah, 2006). This study
examined the effect of EPA in weight-losing patients with advanced gastro-intestinal
or lung malignancy.
Trial 2 - Effect of a protein and energy dense n-3 fatty acid enriched oral supplement
on loss of weight and lean tissue in cancer cachexia; a randomised double blind trial
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(Fearon et al., 2003). This study examined the nutritional supplements in patients
with unresectable pancreatic cancer.
The baseline data from both trials were examined. As this was an analysis of existing
clinical trial data, no additional ethical approval was required. The original studies
had appropriate ethical approval and were conducted in accordance with the
International Committee for Harmonisation, Good Clinical Practice and the Helsinki
Declaration.
6.2.2. Patients
Included patients had gastrointestinal (GI) or lung cancer (trial 1) or unresectable
pancreatic cancer (trial 2). Diagnosis was made on the basis of histological,
cytological, radiological or operative evidence. Included patients had lost 5% or
more of their pre-illness stable weight. Patients were excluded if they were
undergoing tumoricidal therapies, or had undergone chemotherapy, radiotherapy,
surgery in the four weeks prior to study entry. All patients had a Karnofsky
performance status of 60 or more and had an estimated life expectancy of greater
than two months.
6.2.3. Symptom Assessment
Symptoms were assessed using the European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire C-30 (Aaronson et al.,
1993). This is a cancer-specific tool designed to assess symptoms. It includes pain
and fatigue symptoms, and emotional and physical functioning. The pain component
of the EORTC was analysed.
Plasma C-reactive protein was measured at study baseline.
6.2.4. Statistics
Baseline data, common to both studies were combined to create a dataset. This
enabled any possible associations to be investigated. CRP was analysed to allow the
relationship between this and pain to be assessed. Histograms of variables were
inspected and as CRP was judged to be skewed, a transformation was required to
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achieve approximate normality. CRP, in units of mg/dl, was replaced by logio
(CRP+0.1) for analysis.
A regression analysis between pain and CRP was run. Pearson correlation
coefficients were calculated between all pairs of variables.
6.3. Results
6.3.1. Patient Demographics
The characteristics of the patients are presented in Table 18. In total 718 patients
entered the trials, of which 465(64.8%) were men. Lung cancer was the primary
cancer in 231 (32.2%) patients. Two hundred patients (27.9%) had pancreatic cancer
whilst 198 (27.6%) had upper GI cancer. The remainder had lower or unclassified GI
cancer
Both trial populations were well matched, therefore allowing comparison. Patients
had lost on average 17% of their pre-illness body weight and had a BMI of
approximately 22kg/m2. This suggested that patients had moderately severe under¬
nutrition. Lean body mass was approximately 44% of total body weight.
Karnofsky performance status, physical functioning and global health (as defined by
EORTC) were similar in both trials.
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Table 18 - Baseline Demographics




Male 355 110 465 64.8
Female 163 90 253 35.2
Type of cancer
Upper GI 198 198 27.6
Pancreatic 200 200 27.9
Lower GI 83 83 11.6
Lung cancer 231 231 32.2
Unclassified GI Cancer 6 6 8.4
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6.3.2. Relationship between pain and CRP
The relationship between pain and CRP is shown in Table 19. CRP was only
available for analysis in 275 patients in trial 1 and 174 patients in trial 2. There was
no statistical difference in the specific characteristics (e.g. type of cancer, age group,
sex or study centre) between the groups in which CRP was available and those in
which CRP was not.
Table 19 - Relationship between pain and CRP
Trial 1 Trial 2
N=275 N=174
CRP CRP
Pearson Correlation 0.126* 0.163*
Pain Significance (2-tailed) 0.036 0.032
Number of patients 275 174
Correlation significant at the 0.05 level (2-tailed)
Pain positively correlated with CRP in both trials. The Pearson correlation
coefficient was 0.126 and 0.163 for trials 1 and 2 respectively. This correlation was
statistically significant at the p <0.05 level. Patients in trial 2 had a higher correlation
between pain and CRP than in trial 1.
6.4. Discussion
The results demonstrate that pain is related to CRP. As CRP is a surrogate measure
of IL-6, it is reasonable to conclude that pain is related to IL-6, which is a measure of
the pro-inflammatory cytokine response.
The results presented provide some further evidence of the relationship between pain
and systemic inflammation, in cancer patients. The degree of correlation between
pain and CRP, although positive, was low. There was a proportion of patients in
whom CRP was not taken. The reasons for this are not clear but it could be due this
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group being less well, or other reasons which are not readily apparent. As a result
any conclusions that can be drawn are limited. In trial 2, pain was more correlated
with CRP than in trial 1. This may be because patients in trial 2 had pancreatic
cancer which has been associated with chronic systemic inflammation, resulting in
higher CRP levels (McKay et al., 2008).
The results could be interpreted to mean that pain is related to some degree to the
underlying pro-inflammatory cytokine activity, particularly IL-6. These results are in
keeping with the established body of evidence that pain is related to systemic
inflammation, and in particular IL-6.
IL-6 has been shown to be elevated in a number of pain states in animal models. The
administration of IL-6 resulted in allodynia (pain produced from a normally non-
painful stimulus) and thermal hyperalgesia (exaggerated pain response from heat) in
rodent models (DeLeo et al., 1996). Such changes are akin to those seen in
neuropathic pain in humans. In other animal models, where IL-6 is absent (IL-6
knockout mice), physiological pain mechanisms are affected resulting in a
diminished pain response (Ramer et al., 1998). In other types of pain, such as in
animal models of inflammatory pain, IL-6 concentrations are increased (Xie et al.,
2006).
Also of interest is the relationship between pro-inflammatory cytokines (such as IL-
6) and modification of pain processing within the spinal cord. It has been established,
and widely accepted, that the perception of pain is, in part, affected by altered
mechanisms in the spinal cord which occur in chronic pain states. One such
mechanism is glial activation. Glia are the supporting cells within the spinal cord and
are important in pain perception. When chronic pain states exist, glia become
activated resulting in the release of chemicals which can amplify pain (Watkins et al.,
2003). Of these chemicals IL-6 and other pro-inflammatory cytokines produced seem
critical components in the amplification of pain observed following glial activation
(Wieseler-Frank et al., 2004).
Although IL-6 has been mentioned extensively, it is only one of the many pro¬
inflammatory cytokines that exist. It is unlikely that these pro-inflammatory
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cytokines act in isolation and any painful effects that they have are likely to be
produced by a multiple pro-inflammatory cytokine-induced response.
There is considerable evidence to support that other pro-inflammatory cytokines
(Interleukin IB, Tumor necrosis factor-alpha - TNF-a) are also involved (Zhang and
An, 2007).
6.4.1. Implications for practice
The pro-inflammatory cytokine response and the disruption of the normal balance
between pro- and anti-inflammatory cytokines associated with pain, may provide
possible therapeutic opportunities.
IL-6 itself may be a specific therapeutic target. In animal models, pro-inflammatory
cytokines have been shown to diminish analgesia previously provided by opioids in
both acute and chronic pain states (Hutchinson et ah, 2008). As mentioned, IL-6
knockout mice have been shown to have a delayed development of pain, in
controlled studies (Ramer et al., 1998). Such an intervention is unlikely to be
appropriate in humans, although this basic science work clearly illustrates the
important part IL-6 plays in the development of pain. Recently, the role of IL-6 in
cancer pain has been substantiated. In cancer patients in whom polymorphisms in IL-
6 exist, pain severity has been shown to be increased (Reyes-Gibby et al., 2008).
This further supports the role of IL-6 in pain mediation and, in turn, underlines the
potential impact that interfering with this cytokine may have, on the treatment of
pain. The use of human IL-6 receptor monoclonal antibody in inflammatory bowel
disease has been studied and was shown to reduce inflammation (Ito et al., 2004).
The role of IL-6 receptor antibody in cancer pain modulation remains
unsubstantiated thus far, although pilot work has shown inhibitors of TNF-a, are
effective in neuropathic pain of non-malignant origin (Genevay et al., 2004).
In addition to targeting the IL-6 pro-inflammatory response, targeting anti¬
inflammatory cytokines may be appropriate. In patients with chronic pain, decreased
levels of anti-inflammatory cytokines have been demonstrated (Uceyler et al., 2006).
Increasing the relative concentrations of anti-inflammatory cytokines (e.g.
interleukin 4 and interleukin 10) may serve to reduce pro-inflammatory cytokine
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driven inflammation that exists in pain states. It is clear however that there is a third
variable which exists which may affect the results presented. Cancer per se is
associated with inflammation and as disease progresses both pain and inflammation
may increase. In this study the effects of cancer-related inflammation cannot be
disentangled from these findings.
6.5. Conclusion
These findings support the theory that pain is related to systemic inflammation, in
keeping with published work. The majority of previous work was in non-malignant
disease, therefore the relationship between pain and systemic inflammation observed
in cancer is of interest. Inflammation, and in particular pro-inflammatory cytokine
activity, may provide an effective target for the treatment of cancer pain.
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Chapter 7. Symptom Cluster: Pain, Depression and
Fatigue
7.1. Introduction
Symptoms are the physical and psychological manifestations of the underlying
cancer and may be modulated by tumoricidal therapy. Cancer symptoms, however,
rarely exist in isolation and in patients with advanced cancer, a median of 11
symptoms (range 1-27) are present commonly (Walsh et al., 2000).
7.1.1. Symptom Clusters
As many symptoms often co-exist in cancer patients, it has been postulated that
common symptoms may be related. As discussed (Chapter 1), symptoms may be
related in several ways. Symptoms can simply co-exist (e.g. pain and breathlessness),
symptoms can co-exist and be related (e.g. painful hepatomegaly and nausea) or
symptoms can co-exist and share a common pathophysiology.
Symptoms that co-exist and are related to each other have been referred to as
"symptom clusters". In recent years symptom clusters have been increasingly
discussed in the literature. The concept of symptom clusters has provoked debate for
three reasons; how are they defined, what types are there and what is the best way to
model symptom clusters statistically?
7.1.1.1. Defining symptom clusters
In general terms, symptom clusters are symptoms which tend to occur together. It has
been argued that symptoms simply co-existing is insufficient for them to be labelled
as a cluster (Dodd et al., 2004). In a symptom cluster, symptoms need to be related to
each other and occur concurrently.
There is also debate on the number of symptoms required to form a symptom cluster.
Some have suggested that two or more concurrent symptoms that are related to one
another is sufficient to be labelled as a symptom cluster (Kim et al., 2005). Others
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have argued that " three or more concurrent symptoms that are related to each other"
is the most appropriate definition (Dodd et ah, 2001b). This latter definition had been
used extensively and is the most widely accepted.
7.1.1.2. Types of symptom clusters
Due to the large number of potential cancer-related symptoms, the number of
different symptom clusters is vast. Several symptom clusters have been described,
which vary in the number of symptoms in the cluster (ranging from two - five
symptoms) and in their focus (e.g. GI or psychological). There is also a great deal of
overlap between such clusters (Chow et ah, 2008, Wang et ah, 2008, Chen and Lin,
2007). Currently no consensus on specific symptom cluster types has been agreed.
7.1.1.3. Statistical methods of modelling symptom clusters
One of the challenges in modelling symptom clusters is that a different statistical
approach is needed. Although there are various approaches that can be used, a
standardized "best" practice method has not yet been established (Barsevick et ah,
2006). Both factor analysis and cluster analysis have been used to assess symptom
clusters, and these methods do so in different ways. Factor analysis examines
individual variables (or factors), the relations between these variables and identifies a
commonality that links these symptoms (Kim et al., 2005). One of the limitations of
factor analysis is that it serves only to identify the structure of a group of symptoms.
Cluster analysis employs methodology where groups of individuals with the same set
of symptoms, are identified. Both of these approaches have advantages and
disadvantages when applied to symptom cluster analysis. One other approach is to
assess the number of patients with each combination of symptoms and to compare
this to the numbers that would be expected to have these symptoms if there were no
tendency for the symptoms to cluster. This has the advantage of highlighting the
cluster in a more meaningful way, depicting the inherent strength of the cluster, by
showing the co-existing prevalence of symptoms and by comparing this to symptoms
in isolation.
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7.1.2. A symptom cluster of pain, depression and fatigue
Studies have shown that pain, depression and fatigue are highly prevalent and often
co-exist in cancer patients (Glover et ah, 1995, Smets et al., 1998, Gaston-Johansson
et al., 1999, Bower et al., 2000). The symptoms of pain, depression and fatigue and
their possible co-existence as an important symptom cluster was addressed by The
National Cancer Institute in its State-of-the-Science conference (NIH, 2002). It
concluded that there is insufficient evidence to support the concept of a symptom
cluster of pain, depression and fatigue but that more research is required. It has also
been argued that research into symptom clusters should be driven theoretically.
7.1.3. Systemic inflammation as a basis for a symptom cluster of pain,
depression and fatigue
Symptoms may co-exist and also share a common pathophysiology and this may be
the case with pain, depression and fatigue. Systemic inflammation may be a possible
underlying mechanism of this symptom cluster. In animal models, the administration
of inflammatory agents and pro-inflammatory cytokines results in "cytokine-induced
sickness behaviour" (Konsman et al., 2002, Dantzer, 2004). This cytokine-induced
sickness behaviour produces pain and behavioural changes which are comparable
with pain, depression and fatigue in humans (Yirmiya, 1996, Watkins and Maier,
2000). In humans the response to infection, results in increased production of pro¬
inflammatory cytokines (IL-1, IL-6 and TNF-alpha). These pro-inflammatory
cytokines correlate with clinical symptoms which mirror animal models of sickness
behaviour (Vollmer-Conna et al., 2004). Thus in animal models and human studies,
cytokine-induced sickness behaviour resulting in pain, depression and fatigue, has
been shown to exist. These symptoms are similar to those in cancer patients but this
has not yet been examined in the malignant setting.
As discussed in 6.1.2, C-reactive protein (CRP) can be used as a biomarker of
systemic inflammation in cancer (Falconer et al., 1995, O'Gorman et al., 1998,
Crumley et al., 2006). Elevated CRP has been demonstrated in patients with both
early and later stages of disease. The primary stimulus is thought to be a pro¬
inflammatory host-tumour interaction which may depend partly on constitutive
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tumour cell pro-inflammatory cytokine release, but may also relate to a pre-existing
pro-inflammatory tendency in the host (e.g. due to comorbidity or genetic). Systemic
inflammation has been related to anorexia, fatigue, hypermetabolism, weight loss and
shortened survival in a range of types of cancer. The inflammatory response (as
measured by CRP) may therefore be a common physiological pathway for symptom
clusters and signs in cancer patients.
7.1.4. Aim
Although it is has been suggested that pain, depression and fatigue may exist
together as a symptom cluster, this has never been demonstrated in a robust,
systematic fashion. The present study examines this potential cluster and its link with
systemic inflammation, in two different cohorts of patients, with advanced cancer.
7.2. Methods
7.2.1. Overview
Secondary analysis was undertaken of the two existing clinical trial datasets as
described in 6.2.1.
7.2.2. Patients
Patients included had been diagnosed with GI or lung cancer (trial 1) or unresectable
pancreatic cancer (trial 2) as described in 6.2.2.
7.2.3. Symptom Assessment
As discussed in 6.2.3, the European Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire C-30 was used to assess symptoms
(Aaronson et al., 1993). Pain, depression and fatigue were assessed using the
EORTC subscales. Emotional functioning (as per the EORTC) is used as a surrogate
measure of depression/distress. The EORTC questionnaire was completed by all
patients at baseline.
To allow pain, distress (depression) and fatigue to be defined, thresholds were
chosen for the each of the various EORTC subscales as shown in Table 20.
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Table 20 - EORTC thresholds
Symptom EORTC Sub-scale Threshold for a positive
diagnosis
Pain Pain Symptoms >50
Distress(Depression) Emotional function <70
Fatigue Fatigue Symptoms >60
7.2.3.1. CRP measurement
C-reactive protein was measured at baseline.
7.2.4. Statistics
The dataset as described in 6.2.4 was utilised. An analysis of symptom clusters was
undertaken. To allow data analysis, cut-off points for each of the EORTC symptom
subscales, were determined. This was done to get approximately 50% of the patients
over both studies, to have each symptom, to enable a comparison between the
observed prevalence of symptoms if clustering was present and an expected
prevalence of symptoms, if clustering did not exist. This had the advantage that if
there was no tendency for the symptoms to cluster, then approximately one-eighth of
the patients would have each of the 8 possible combinations of the 3 symptoms.
As was the case in 6.2.4, CRP was skewed so a transformation to logarithms was
done. Kruskal-Wallis test was performed between the median CRPs (mg/dl) of all
possible symptom combinations.
For the sake of brevity, in the results and discussion sections that follow, the term
"depression" is used when describing the EORTC emotional functioning analysis.
Clearly depression is only truly diagnosed via a gold standard psychiatric interview.
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7.3. Results
7.3.1. Patient Characteristics
The characteristics of the patients are as presented in Chapter 6 - Table 18.
7.3.2. Symptom Clusters
The results of the symptom cluster analysis are presented in Table 21 and Table 22.
Although 718 patients entered the studies, EORTC symptom data were only
available on 654 patients (473 trial 1, 181 trial 2) for the symptom cluster analysis.
The numbers of patients assessed for the symptom cluster analysis is smaller than the
total number of patients because the analysis was based on patients who had pain,
depression and fatigue all recorded. Missing data resulted in the overall numbers
being lower.
The various observed and expected symptom prevalences are presented. These were
sub-divided into the total sample and CRP sample (the group of patients in which
CRP was available). There was no statistical difference in the specific characteristics
(e.g. type of cancer, age group, sex or study centre) between the total sample and the
sample of patients where CRP was available.
Data on all three symptoms (pain, depression and fatigue) and CRP, were available
in 264 patients in trial 1 and 172 patients in trial 2.
7.3.2.1. Trial 1
The results are shown in Table 21.
Total Sample
One hundred and thirty (27.5%) patients had no symptoms of pain, depression and
fatigue. This was considerably higher than the expected number of participants who
were thought to have no symptoms (71.2 [15.1%]). There was clear evidence of pain,
depression and fatigue clustering with 101(21.4%) patients having this combination
of symptoms. This is more than double the number of participants (21.4% compared
with 9.9%), that would be expected to have this combination of symptoms. In all
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other possible symptom combinations, the observed prevalence was less than the
expected prevalence of symptoms.
Sample of patients with CRP available
In the group of patients who had CRP taken, findings were in similar proportion to
the total sample. With the exception of those with no symptoms and those with all
three symptoms, the observed prevalence of symptoms was less than the expected
prevalence. Pain, depression and fatigue were present together in a greater proportion
of patients than would be expected if clustering were not present (18.2% compared
with 7.2%).
The median CRP for all possible symptom combinations was analysed. There was no
statistically significant difference between the median CRPs, between each of the
various possible symptom combinations.
7.3.2.2. Trial 2
The results are shown in Table 22.
Total Sample
Fifty-eight (32.0%) patients had no symptoms of pain, depression and fatigue. This
was approximately 50% higher than the expected number of participants who were
thought to have no symptoms (39.0 [21.6%]). There was evidence of pain,
depression and fatigue clustering with 28 (15.5%) of patients having this
combination of symptoms. This was approximately 2.5 times the number of
participants (15.5% compared with 6.3%) that would have been expected to have this
combination of symptoms. In all other possible symptom combinations, the observed
prevalence was less than the expected prevalence of symptoms.
Sample of patients with CRP available
There were similar findings in this group of patients, to the total sample. With the
exception of those with no symptoms and those with all three symptoms, the
Symptom Clusters: pain, depression and fatigue 85
observed prevalence was less than the expected prevalence. Pain, depression and
fatigue were present together in a greater proportion of patients than would be
expected if clustering were not present (16.3% compared with 6.2%).
The median CRP for all possible symptom combinations was analysed. The median
CRPs for trial 2 were higher than those in trial 1. There was no statistically
significant difference between the median CRPs across each of the various possible
symptom combinations.
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7.3.2.3. CRP and relation to symptoms
CRP was measured in 436 patients (264 trial 1, 172 trial 2) and an analysis of CRP and its
relation to pain, depression and fatigue, was done.
Figure 7 and Figure 8 show the boxplots for CRP for trials 1 and 2 respectively. This does not
support an association between CRP and the type and number of symptoms.
Table 23 shows the sample data and median CRPs from both trials. Patients in trial 1 had
more symptoms in all groups, than those in trial 2. The cluster of pain, depression and fatigue
was also more common in trial 1. In contrast median CRPs were higher in trial 2 than in trial
1.
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7.4. Discussion
The study supports the symptom cluster of pain, depression and fatigue in cancer
patients. There are more patients with all three symptoms than would be expected.
The findings also show that each symptom can occur in isolation and every possible
pair of symptoms can occur without the third being present. When single, or pairs, of
symptoms do occur this is often less than would be expected which further supports
the existence of pain, depression and fatigue as a specific symptom cluster. Although
this cluster is suggested, it cannot be deduced that screening for one of these
symptoms will identify the other symptoms in the cluster.
The role of systemic inflammation as a possible basis for the symptom cluster of
pain, depression and fatigue has not been demonstrated in this analysis. The boxplot
and summary statistics do not support an association between CRP and the type and
number of symptoms.
Overall, the results demonstrate a clear tendency for a symptom cluster of pain,
depression and fatigue, in a large cohort of cancer patients. There were, however,
considerable differences between the two trial groups. This may be in part to the
different patient populations. Patients in trial 1 had either GI or lung cancer whilst all
those in trial 2 had pancreatic cancer. Patients in trial 1 had a higher prevalence of
symptoms overall which may have been due to a greater burden of metastatic
disease. Metastatic disease is likely to result in a higher symptom burden. Pancreatic
cancer is associated with cachexia which, in turn, is associated with systemic
inflammation (McKay et al., 2008). This may have resulted in the higher median
CRP, seen in this group.
7.4.1. Comparison of findings with other work
The need for evidence to support the cluster of pain, depression and fatigue has been
identified as a research necessity (NIH, 2002). Previous work examining symptom
clusters has been undertaken, however comparison is difficult, due to differing
symptom assessment tools and methodological analysis.
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A prevalence study of 1000 patients reported that pain, depression and fatigue, co-
occur in 1 in 4 cancer patients (Hauser et al., 2006). This is slightly higher than that
reported here but a different definition of symptoms, and different patient groups and
statistical analysis, were used making a direct comparison challenging. A study of
lung cancer patients has supported the symptom cluster (pain, depression and
fatigue) although this was in combination with other symptoms (Wang et al., 2008).
In a study of 321 patients with various primary cancers, pain and fatigue have been
reported as clustering together (in combination with disturbed sleep, anorexia and
drowsiness) (Chen and Lin, 2007). This study did not support depression clustering
with pain and fatigue; however this was in a heterogeneous group. To date there has
been no robust evidence to support pain, depression and fatigue as a symptom cluster
in cancer patients.
7.4.2. A biological basis of symptom clusters
Systemic inflammation has been suggested as a possible underlying mechanism for a
symptom cluster of pain, depression and fatigue. This was the rationale for the
analysis of CRP (as a surrogate measure of systemic inflammation) undertaken in
this study and its relation to pain, depression and fatigue. Although the results do not
support systemic inflammation as a possible underlying mechanism, this may be due
to the fact that CRP was used. CRP is a sensitive marker of inflammation but is not
specific and may been affected by other variables (Tsilidis et al., 2008).
Systemic inflammation, as one possible mechanism for the symptom cluster of pain,
depression and fatigue, would seem plausible. Basic science work and studies in non-
malignant disease in humans, would support cytokine-induced sickness behaviour as
a possible biological basis for the symptom cluster of pain, depression and fatigue.
Currently, however, there is insufficient evidence to support cytokine-induced
sickness behaviour as a mechanism for a symptom cluster of pain, depression and
fatigue in cancer patients.
7.4.3. Limitations
Studying symptom clusters in cancer patients is challenging. Consideration should be
given to the many dimensions that affect symptom clusters and the effects these can
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have on the examination of clusters (Barsevick et al., 2006). The type of cancer,
staging and current therapy can affect magnitude of the symptoms studied (Barsevick
et al., 2006).
It has been argued that when examining symptoms clusters, a longitudinal study
design is best (Armstrong, 2003). This allows the evolution of symptoms, and their
relationships to each other to be examined. The study presented here examines
symptom clusters at a single point in time which may not have allowed the dynamic
relationship between these symptoms to be fully appreciated.
The study population comprised lung, GI and pancreatic cancer patients, all with a
degree of weight loss. As a result, the generalisability of the findings may be limited.
However, it is possible to regard this as one of the strengths of the study as several
different cancers are included. Furthermore, as these cancers often produce a high
symptom burden, it could be argued that these groups were an ideal cohort in which
to study symptom clusters.
7.5. Conclusion
The study results support the presence of pain, depression and fatigue as a symptom
cluster. There is insufficient evidence to suggest that systemic inflammation (as
measured by CRP) is an underlying mechanism. Although the results support pain,
depression and fatigue as a cluster, there is insufficient evidence to support that
screening for one or two of these symptoms will identify everyone who has this
cluster.
The cluster of pain, depression and fatigue demonstrated here may have implications
for practice. The direct treatment of one symptom (e.g. analgesia for pain) may
indirectly reduce another symptom in the cluster which may in turn mean that
diagnosing these symptoms in isolation may be of less importance than previously
thought. It would seem likely that diagnosis and treatment of individual symptoms
will remain the primary focus, although the impact that individual treatment may
have on other symptoms, should be appreciated fully.
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Basic science work suggests that systemic inflammation (mediated through cytokine-
induced sickness behaviour) can result in pain, depression and fatigue. Although it
cannot be supported here, the presence of the cluster and the small degree of
heterogenecity of the patients within this study raises the likelihood that the
underlying mechanism may not differ among cancer types.
Future work should examine the symptom cluster of pain, depression and fatigue in
the broader cancer population. Systemic inflammation as a possible underlying
mechanism of this cluster requires further examination. If a common underlying
modality is identified, therapeutic targets could be developed to address the
underlying pathological mechanisms, targeting each treatment at the cellular level.
This would have considerable implications for clinical practice.
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Chapter 8. Conclusion
The difficult cancer pain states (neuropathic cancer pain and cancer induced bone
pain) have been examined and physical and psychological components have been
explored.
Neuropathic cancer pain and CIBP have never been characterized clinically, in a
robust systematic fashion. In doing this, detailed characteristics have been gathered
about these common but challenging cancer pain states. The findings in neuropathic
cancer pain and CIBP have implications for the assessment and management of these
pain states.
In neuropathic cancer pain and CIBP, worst pain is predictive of the interference
score of the BPI. The interference component of the BPI gives a meaningful measure
of the impact pain is having on patients' lives and is likely to be more important to
patients than a 0-10 pain score. Worst pain is predictive over and above average pain
suggesting that if a single measure is to be used in assessing these pain states, worst
pain is the key assessment.
Breakthrough pain in neuropathic cancer pain and CIBP has been examined in detail.
In these pain states, the detailed examination of breakthrough pain has revealed some
important characteristics. Frequently, breakthrough pain is unpredictable, rapid in
onset, severe in intensity and short in duration. Between 40-50% of patients in both
groups had breakthrough pain which was of rapid onset (less than 5 minutes) and
short duration (less than 15 minutes).
Although studies of breakthrough pain in cancer have been carried out previously,
this was in heterogeneous groups of cancer pain, resulting in a great degree of
variation in breakthrough pain characteristics (Portenoy et al., 1999, Gomez-Batiste
et al., 2002). As these studies presented here examine specifically the pain states of
neuropathic cancer pain and CIBP, an accurate characterization has been realized.
The temporal characteristics of neuropathic cancer pain and CIBP would suggest that
IR opioids (e.g. oral morphine) are unlikely to be effective in a considerable
proportion of patients. Newer, rapid-onset fentanyl preparations may address this to
Conclusion 97
some extent; however there will continue to be patients for whom our current
armamentarium of analgesics will be ineffective.
There is a clear need for a greater understanding of the underlying processes which
exist in these pain states. Basic science and translational work has already suggested
that there may be key differences in these pain states at the cellular level and this
may influence how these pain states are managed (Luger et ah, 2002, Urch and
Dickenson, 2008). Such work could result in a radical change of practice where such
pain states are successfully controlled through a proactive, as opposed to the current,
reactive approach. Fundamental to this development is the issue of specific adjuvant
analgesics.
The relationship between cancer pain and depression may also be explained at the
cellular level in the future. The work presented here does not support categorically, a
relationship between pain and depression. This may be due to the lack of
appropriately designed studies (as highlighted in Chapter 4), although it is clear that
some pain features (such as intensity and duration of pain) are related to depression.
The longitudinal study of pain and depression in Chapter 5 presents some key
findings. Treating pain decreases the HADS score, whereas if pain does not improve,
the HADS score increases. As the HADS is a screening tool and not diagnostic of
depression, limited inferences can be drawn. Distress and pain may be associated but
this has not been clearly demonstrated. Furthermore, as distress is hard to quantify, it
is challenging to draw any meaningful conclusions. Future work examining a
possible relationship between pain and depression will require a broad sample of the
cancer population and formal assessment of depression.
If an interdependent relationship between pain and depression exists it may influence
the treatment of these symptoms. A multimodal approach may be warranted with the
specific targeting of common neurotransmitters and pathways.
Chapter 6 has demonstrated the relationship between cancer pain and systemic
inflammation. Pain is related to systemic inflammation and this supports both basic
science work and work in non-malignant disease. This relationship is of particular
interest and may provide another avenue for the treatment of cancer pain. As
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previous chapters have illustrated current therapies can be ineffective and it is
important that new treatments are based on a strong scientific foundation. Although
current anti-inflammatory therapies (e.g. IL-6 monoclonal receptor antibody) are not
widely used, there is clearly strong supporting evidence that new treatments targeting
inflammation, may be of benefit.
Chapter 7 has shown that pain, depression and fatigue exist together as a specific
symptom cluster. This supports the possible relationship between pain and
depression and demonstrates further that symptoms rarely exist in isolation. Systemic
inflammation as a possible underlying basis for this was not supported; however this
may be due to the biomarker (CRP) that was used here. Currently, there is
insufficient evidence to support the premise that only one symptom in a cluster
should be treated and other symptoms will improve without intervention. It is
reasonable to assume, however, that if one symptom in a cluster does improve, there
may be an improvement in other symptoms.
This thesis has presented some key challenges for the future assessment and
management of these symptoms. Breakthrough pain requires to be assessed
specifically to enable a true measure of the impact of neuropathic cancer pain and
CIBP. The temporal characteristics of these pain states mean that current and novel
therapies are often sub-optimal. Future work needs to be based on a solid basic
science foundation and therapies should meet the specific nuances of these cancer
pain states.
Assessing symptom relationships at a clinical level is testing. Nevertheless, this
should not discourage further, appropriately powered and designed work to assess
these relationships in the hope of translating into an improvement in the physical and
psychological components of cancer pain.
Future work should continue to examine the fundamental components of cancer pain
and in particular, broader studies examining CIBP and neuropathic cancer pain are a
necessity. Examination of these key areas will be aided by basic science. The
emerging fields of translational research in symptom management and detailed
examinations of cancer pain syndromes and psychological symptoms are to be
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embraced. These developments are fundamental to building on the foundations of
palliative care already laid; that optimum physical and psychological symptom





STUDY ID#. HOSPITAL #.
DO MOT WRITE ABOVE THIS LIME
Brief Pain Inventory (Short Form)
Esa /. l inn:-*
Last First MiddUe Initial
1. Throughout our lives, most of us have had pain from time to time (such as minor
headaches, sprains, and toothaches). Have you had pain other than these every¬
day kinds of pain todaVIA
1. Yes 2. No
2 On the diagram, shade in the areas where you feel pain. Put an X on the area that
hurts the most.
3. Please rate your pain by circling the one number that best describes your pain at Its
0 12 3 4 5 6 7 8 9 10
No Pain as bad as
Pain you can imagine
4. Please rate your pain by dicing the one nulmber that best describes your pain at Its




3 4 6 7 8 9 10
Pain as bad as
you can imagine





3 4 6 7 8 9 10
Pain as bad as
you can imagine
6. Please rate your pain by circing the one number that tells how much pain you have
right now.
0 1 2 3 4 5 6 7 8 9 10
No Pain as bad as
Pain you can imagine
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7. What treatments ormedications are you receiving for your pain?
8. In the last 24 hours, how much relief have pain treatments ormedications
provided? Please circle the one percentage that most shows how much fnraa
you have received.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No Complete
Relief Relief
9. Circle the one number that describes how, during the past 24 hours, pain has
interfered with your:
















[b. Normal Wortt (Includes both work outside the home and housework) 1





E. Relations with other peopleI























1. Thinking about your usual or background pain, on average, how severe has this
been in the last 24 hours? (please circle how severe the pain has been).
0123 4 5 6 7 8 9 10
2. In the last 24 hours, how many times has your pain flared up or become severe?




3. Ifmore than 10, how many times: Not sure
4. In the last 24 hours on average, how severe does the pain become when it flares
up? (please circle how severe the pain has been).
0123456789 10
5. Over the last 24 hours, on average, how long does the flare up of pain last for?
(please circle the number of minutes)
(less than lmin) (l-15mins) (16-30mins) (31-60mins)
(60-120mins) (more than 120 mins)
6. Over the last 24 hours, on average, from the time you first feel this pain start to
flare-up or worsen, how long does it take to get as bad as it gets?
(please tick the appropriate box)
Unpredictable □ 6 minutes to 30 minutes □
Less than 10 seconds D 31 minutes to 60 minutes q
10 seconds to 5 minutes D
7. Are you able to tell or predict when your pain is going to flare-up or become
severe? (please circle the phrase that most closely represents what you think)
never sometimes often almost always always
8. How often do you take extra pain killers or a "rescue" dose for your flare ups of
pain? (please circle the response that you feel most accurately describes what normally
happens)
every time most of the time some of the time hardly ever never
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Paper assessment pro forma









2.0 Is depression clearly defined? YES NO UNSURE
2.1 If yes, what method was used to record this? (eg
HADS, Beck Depression etc)
3.0 Is pain clearly defined? YES NO UNSURE
3.1 If yes, what method is used to record this?
(eg VAS, numerical rating etc)
4.0 What was the sample size?
4.1 Does study sample include cancer patients YES NO UNSURE
5.0 Does the paper explore the relationship between
pain and depression?
YES NO UNSURE
5.1 Was study population divided into this either with
or without pain or those with or without
depression?
YES NO UNSURE
5.2 If YES what factor separated the groups? Pain Depression
6.0 Does this study help to answer your key question:
is cancer pain and depression related?





Hospital Anxiety and Depression Scale
Doctors are aware that emotions play an important part in most illnesses. If your
doctors know about theses feelings he will be able to help you more. This
questionnaire is designed to help your doctor know how you feel. Read each item
and place a firm tick in the box opposite the reply which comes closest to how you
have been feeling in the past week. Don't take too long over your replies; your
immediate reaction to each item will probably be more accurate than a long thought
out response.
Tick only one box in each section
I feel tense or 'wound up': I feel as if I am slowed down:
Most of the time Nearly all of the time
A lot of the time Very often
Time to time, occasionally Sometimes
Not at all Not at all
I still enjoy the things I used
to enjoy:
I get a sort of frightened
feeling like 'butterflies in the
stomach':
Definitely as much Not at all
Not quite so much Occasionally
Only a little Quite often
Not at all Very often
I get a sort of frightened
feeling like something awful
is about to happen:
I have lost interest in my
appearance:
Very definitely and quite badly Definitely
Yes, but not too badly I don't take as much care as I
should
A little, but it doesn't worry me I may not take quite as much
care
Not at all I take just as much care as ever
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I can laugh and see the funny
side of things:
I feel restless as if I have to
be on the move:
As much as I always could Very much indeed
Not quite so much now Quite a lot
Definitely not so much now Not very much
Not al all Not at all
Worrying thoughts go
through my mind:
I look forward with
enjoyment to things:
A great deal of the time A much as I ever did
A lot of the time Rather less than I used to
From time to time but not too
often
Definitely less than I used to
Only occasionally Hardly at all
I feel cheerful: I get sudden feelings of
panic:
Not at all Very often indeed
Not often Quite often
Sometimes Not very often
Most of the time Not at all
I can sit at ease and feel
relaxed:
I can enjoy a good book or
radio or TV programme:
Definitely Often
Usually Sometimes
Not often Not often
Not at all Very seldom
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Laird BJA, Scott AC, Todd AMH, Colvin LA, Fallon MT. Are pain and depression
interdependent in cancer: a longitudinal study. Proceedings from the EAPC Congress.
European Journal of Palliative Care 2009. (Invited Lecture)
Aims: Pain and depression are highly prevalent symptoms in cancer patients.
Epidemiological studies have shown that pain and depression often co-exist and thus the
relationship between these symptoms is of interest. Studies have shown a statistically
significant association between pain and depression and it has been suggested that these
symptoms may be inter-dependent. Although associations exist, there are no published
studies that examine the relationship between these symptoms. The aim of this study is to
examine the relationship between cancer pain and depression.
Methods: 60 patients with advanced cancer and cancer induced bone pain were assessed as
part of this study. All patients had assessments of mood (Hospital Anxiety and Depression
Scale) and pain (Brief Pain Inventory) at study baseline. Patients then received a therapeutic
intervention (radiotherapy + optimisation of analgesia). Further assessments of mood and
pain were undertaken four weeks from study baseline. No patients had commenced
antidepressant medication (in the four weeks prior to study entry) or had started
antidepressants during the study period.
Results: Full statistical analysis of study results is awaited. Preliminary results show an
improvement in pain following the therapeutic intervention. The median total BPI score pre-
and post- intervention was 49 (range 32-88) and 13 (range 0-52) respectively. The median
total HADS score pre- and post- intervention was 13 (range 2-22) and 9 (range 1-18)
respectively. In patients who had a 30% or more reduction in their BPI score (total score)
there was a statistically significant reduction in HADS score (p<0.05).
Conclusions: This is the first study that examines the natural evolution of anxiety and
depression in patients with pain who have pain treated actively, whilst no anti- depressive
intervention is administered. Results support the theory that the active treatment of cancer
pain results in an improvement in anxiety and depression.
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Laird BJA, Walley J, Murray G, Colvin LA, Fallon MT. What is the key question in the
assessment of Cancer Induced Bone Pain: results from a characterisation study. British
Pain Society Annual Scientific Meeting, London, April 2009. (Published Abstract)
Aim: Cancer induced bone pain (CIBP) is a common cause of pain in patients with cancer.
CIBP is associated with increased morbidity, reduced performance status, increased anxiety
and depression, and a reduced quality of life. CIBP is also a considerable therapeutic
challenge. Palliative radiotherapy remains the most effective anticancer treatment for CIBP
however it is not always effective and only one quarter of patients will get complete pain
relief. Opioid analgesia is the main pharmaceutical treatment for CIBP however titration of
opioids to doses that control spontaneous bone pain and movement-related bone pain, usually
results in unacceptable opioid side-effects. Recently rapid-onset, short-duration opioids have
been suggested for breakthrough pain in CIBP and other pain types. Despite the clinical time
invested in trying to help patients with CIBP and the development of new analgesic
strategies, CIBP has never been characterised in the clinical setting. Detailed characterisation
is fundamental to meaningful clinical and translational research, and to develop more
effective analgesic strategies. The aim of this study was to characterise CIBP.
Patients and methods: A cross-sectional survey of patients with CIBP in a regional
oncology centre. Patients had a radiologically proven site of bone metastases and pain in
keeping with this site. A single interview was conducted with each patient during which the
Brief Pain Inventory (BPI) and a screening question to identify breakthrough pain were
completed. Patients who had breakthrough pain also completed a Breakthrough Pain
Questionnaire (BTPQ). Statistical analysis was performed. BPI "average pain" and "worst
pain" scores were then compared to the total BPI interference scale. Regression analyses
between these variables were then run. The relationships between these pain scores and pain
related interference with function, were then determined. A subgroup analysis of the BPI was
undertaken to compare those patients with, and those without, breakthrough pain.
Results: 55 patients were recruited, 28 (49.1%) were male and the mean age was 63.7 years.
Median average pain was 4, median worst pain was 7. BPI worst pain correlated more
strongly with BPI total interference than average pain score. Patients who had breakthrough
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pain had significantly higher total BPI interference scores than those who had no
breakthrough pain (median (IQR); 18.5 (5.5-26.7) vs 35.0 (21.5-44.7) p<0.01). The median
severity of the breakthrough pain was 8 (based on a 0-10 VAS). The speed of onset of pain
was less than 5 minutes in 33 patients (78.6%). 20 patients (48.1%) had breakthrough pain
which was rapid onset (less than 5 minutes) and of short duration (less than 15 minutes). 18
patients (43.9%) had pain which was unpredictable
Conclusion: These data provide the first systematic characterisation of cancer induced bone
pain. Single measures of pain are unlikely to describe CIBP, but if a single measure is to be
used, BPI "worst pain" most accurately reflects the characteristics of breakthrough pain and
associated functional impairment. Breakthrough pain is highly prevalent in patients with
CIBP. This is often unpredictable, rapid onset and short duration. Patients with breakthrough
pain have higher BPI interference scores than those with no breakthrough pain highlighting
the importance of breakthrough pain to patients' physical and psychological well-being.
Our findings suggest that current management strategies for treating CIBP are likely to be
inadequate for a sizeable number of patients. An improved opioid armamentarium will be
useful for some patients however those patients with rapid onset, short-duration breakthrough
pain, will remain challenging. Some basic science work also questions if CIBP is opioid
responsive suggesting a different underlying pathophysiology from background CIBP.
Further research is required to develop effective delivery systems for rapid onset, short acting
opioids that reflect the characteristics of the breakthrough pain that commonly affect patients
with CIBP.
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Laird BJA, Murray GM, Colvin LA, Fallon MT, Fearon KCH. Symptom clusters in
advanced cancer: role of systemic inflammation. Proceedings from the EAPC Congress.
European Journal of Palliative Care 2009. (Published Abstract)
Aims: Cancer symptoms rarely exist in isolation and in recent years the concept of symptom
clusters has been increasingly discussed in the literature. Systemic inflammation has been
suggested as a possible underlying mechanism of cancer symptom clusters. This study
examines whether pain, depression and fatigue exist as a symptom cluster. The relationship
of C-reactive protein (CRP- as a measure of pro-inflammatory cytokine activity) to pain,
depression and fatigue is examined and a possible biological explanation of these cancer
symptoms is explored.
Design and methods: Analysis was undertaken of two large cancer trials (n=718).
Symptoms were assessed using the European Organisation for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire C-30. Measurement of plasma CRP was
performed. Multivariate analysis was undertaken and Pearson correlation coefficients were
calculated between all pairs of variables. A series of regression analyses were run relating
pain, depression, fatigue and CRP.
Results: Pain, fatigue and emotional functioning (mood) were strongly related (correlation
significant at the 0.01 level - 2 tailed). CRP was related to pain and fatigue (to levels of
statistical significance, p<0.05). CRP was positively correlated with emotional function but
this did not reach levels of statistical significance.
Conclusions: In this dataset, there are strong associations between pain, fatigue and mood.
This apparent symptom cluster has a statistical relationship with plasma CRP. While we
cannot conclude a definite causal relationship between systemic inflammation (CRP) and this
cluster of symptoms, these results give a strong indication that further elaboration of this
concept could be of great clinical interest as well as moving the research agenda forward.
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Laird BJA, Boyd A, Colvin L, Fallon MT. Cancer Pain and Depression; A systematic
review. Palliative Medicine 2008;22(4):481 (Published Abstract)
Introduction: A single point prevalence survey demonstrated that approximately 90% of
patients with cancer experience pain. Depression occurs in approximately one quarter of
advanced cancer patients. The relationship between depression and pain is of great
importance in routine clinical practice.
Aim: The aim of this systematic review is to examine the relationship between cancer pain
and depression.
Methods: An extensive literature search was undertaken. The following databases were
searched electronically: Medline (1950-2007), Embase (1988-2007), Cinahl (1982-2007) and
the Cochrane Database of Systematic Reviews (Issue 2 2007). Relevant journals were also
searched by hand.
Results: As a consequence of a broad search strategy, 892 articles were identified. A
consensus was reached that 41 papers were suitable for detailed review using a pre¬
determined proforma. Subsequently 14 articles were deemed appropriate for inclusion. The
mean prevalence of depression and pain was 31.5% (range 20.2 - 46.0) and 63.3% (range 37-
100%) respectively. In 10 out of 14 studies a statistically significant association was
demonstrated between pain and depression: Pain intensity positively correlated with
depression (to levels of statistical significance p<0.05). Pain interference items such as
"worst pain" and "enjoyment of life"(measured on the BPI) correlated significantly with
depression. When using the McGill Pain Questionnaire, depressed patients used more
affective descriptors. It was also shown that the longer the duration of pain, the higher the
risk of depression. Conversely as pain decreased so did depression, to levels of statistical
significance.
Conclusions: Both pain and depression are highly prevalent in cancer patients however there
have been no appropriately designed studies to examine a causal relationship. A suitably
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